


ADVANCING PHARMACY AND SCIENCE  
TO THE BENEFIT OF THE PATIENT



2007  
ANNUAL REPORT 8



ADVANCING PHARMACY AND SCIENCE  
TO THE BENEFIT OF THE PATIENT



2007  
ANNUAL REPORT 8



# Contents

Introduction - Message from the President .....	3
FIP - The Year in Review .....	5
Congress Report .....	13
Board of Pharmaceutical Sciences Report .....	17
Board of Pharmaceutical Practice Report .....	25
Academic Pharmacy Section .....	29
Administrative Pharmacy Section .....	33
Clinical Biology Section .....	35
Community Pharmacy Section .....	38
Hospital Pharmacy Section .....	43
Industrial Pharmacy Section .....	48
Laboratories and Medicines Control Services Section .....	52
Military and Emergency Pharmacy Section .....	54
Pharmacy Information Section .....	58
Regional Pharmaceutical Forums .....	63
African Pharmaceutical Forum (APF) .....	63
Pharmaceutical Forum of the Americas .....	66
EuroPharm Forum .....	68
South-East Asia (SEARpharm) Forum .....	70
Western Pacific Pharmaceutical Forum .....	75
FIP Young Pharmacists Group .....	79
FIP and WHO: FIP expands at home and abroad -	
A Message from the FIP General Secretary .....	83
WHO-FIP Status Report - January 2007 - April 2008 .....	85
Progress Report: Global Pharmacy Education Taskforce .....	91
Finance .....	95
FIP Contact Details .....	96



# Introduction

## Message from the President

Dear Colleagues,

As we look back over the past year, it is with gratitude and enthusiasm that we present and celebrate the many accomplishments of you, our members and of FIP's governing body, sections, committees, regional forums and working groups, all of whom are active on your behalf. Although these are busy, demanding times - times of escalating challenges and exciting possibilities for all of us - during this past year, we have felt the need to make time for careful reflection and renewal of the Federation's vision. We have taken stock of where we have come from and where we are today, through the dedicated contributions of so many. Based on our achievements, we have been contemplating the best way to move forward together to meet future needs. We have deliberated, taking into consideration, our vision, the mission and strategic objectives of FIP in our rapidly and constantly changing reality of global healthcare. We have asked ourselves how we - our members and FIP collectively - can best contribute to global health. As we reviewed the achievements of our Federation founded in the year 1912, we are looking forward to celebrating our 100<sup>th</sup> anniversary in four years. We also look forward to year 2020 to bring the ideals and spirit of FIP to another generation of pharmacists and pharmaceutical scientists aimed at serving global health needs more effectively.

In July 2007, we began our deliberations of revisiting and renewing our Mission, Vision and Strategic Plan. In carefully examining our current strategies and their effectiveness, we communicated with the external partners and advisors. We analysed external global trends, drawing on the expertise and generosity of our FIP community to arrive at what we believe is a renewed and reinvigorated vision and mission for the strategic goals and daily activities of FIP on the global stage of healthcare. The fruit of these deliberations - *Vision 2020: FIP's Vision, Mission and Strategic Plan* - will be released to our Council Members at the 2008 FIP Congress in Basel, Switzerland. It is our hope and goal that this document and the collective FIP aspirations it embodies will effectively proclaim and fulfil our integral role as pharmacy professionals and associations in the global healthcare community.

During this past year, our work in pharmacy education has taken large strides. We are anticipating a major tripartite agreement with the World Health Organization (WHO), UNESCO and FIP. The first of its kind, this agreement focuses on drawing on and incorporating the influence and expertise of the academic, health and professional sectors for the development of pharmacy education and workforce issues based on local needs. These goals and aspirations will form the basis of our discussions in the 4<sup>th</sup> FIP Roundtable on Pharmacy Education at the 2008 FIP Congress in Basel.

The Federation continues to develop and strengthen its partnerships. In our co-operation with WHO, we are an integral partner in addressing such key issues as counterfeit medicines. We jointly planned the 1<sup>st</sup> Global IMPACT Forum, bringing together industry and regulators in open communication about counterfeit medicines. Our work within the World Health Professions Alliance continues to benefit all the partners in such issues as healthcare regulation. Our participation has meant increasing

recognition of the contributions that the knowledge and expertise of pharmacists and pharmaceutical scientists make to the rational use of medicines, patient safety and multi-disciplinary inter-professional patient care. Such collaborations among global healthcare organisations and professionals that is patient-focused, medicine centred, results in improved global healthcare based on effective knowledge transfer and efficient healthcare systems.

The fact that FIP has remained steadfast to its founding ideals, whilst moving forward into new areas and partnerships, is a testament to the Federation and to those who dedicate their time, effort and care, to its advancement. At the core of this Federation are our members. During the past year, I have had the privilege to meet and speak with many FIP member organisations. Over the past several months, I have been deeply gratified and greatly inspired to discover the high regard with which FIP and our initiatives are held. The values and practices we strive to achieve transcend the differences of cultural and socio-economic demographics. When speaking to members in Jordan, India, Uganda, Korea and the United States, I witnessed first-hand the deep aspirations and ideals of FIP member associations at work. As pharmacists and pharmaceutical scientists worldwide, we aspire to make the greatest, positive impact possible on the good health of our patients and their communities.

The year 2007-2008 has been one of growth and renewed dedication for FIP. Our vision is steadfast. Our professional practices, education and collaborations are stronger. Without underestimating the daunting challenges we face and with confidence we welcome the opportunities of serving our member organisations in ensuring the highest quality of public healthcare world-wide. This Annual Report provides an overview of this past year while presenting the foundation of Vision 2020 that is launching FIP into the future. I welcome your participation and dedication to our collective professional responsibility as pharmacists and pharmaceutical scientists. Together we have made a difference. It is my deepest confidence that we will continue to make a difference.



Dr Kamal K. Midha  
*FIP President*



# FIP

## The Year in Review

### FIP in Numbers

In the 2007-2008 period to date, FIP Membership increased to **3798** Members, including Member Organisations and Individual Members, with **320** new **8** cancellations of Individual Members over that time frame.

Number of Individual FIP Members 2007

Start 2007 (01/01/2007)	3486
New members	320
Cancellations	8
End 2006 (31/12/2007)	3798

### FIP Representation by Country



- Country with Member Organisation
- Country with Individual Members Only

# FIP Member Organisations

Argentina	Confederación Farmacéutica Argentina
Armenia	Pharmprogress NGO
Australia	Pharmacy Guild of Australia
	Australasian Pharmaceutical Science Association (APSA)
	Pharmaceutical Society of Australia
Austria	Österreichischer Apothekerverband
	Österreichische Apothekerkammer
Bosnia & Herzegovina	Association of Pharmacists of the Federation of Bosnia and Herzegovina
	Pharmaceutical Society of the Republika Srpska
Brazil	Federal Council of Pharmacy
Bulgaria	Bulgarian Scientific Pharmaceutical Association
Burkina Faso	Ordre National Des Pharmaciens du Burkina Faso
Cameroon	Conseil National de l'Ordre des Pharmaciens Cameroun
Canada	Canadian Society for Pharmaceutical Sciences
	Canadian Pharmacists Association
China	Chinese Pharmaceutical Association
China Taiwan	Pharmaceutical Society of China Taiwan
	Taiwan Society of Health System Pharmacists
Colombia	Col. Nac. de Quimicos Farmaceuticos de Colombia
Congo (Rep. of)	Conseil National de l'Ordre des Pharmaciens du Congo
Costa Rica	Colegio de Farmaéuticos de Costa Rica
Côte d'Ivoire	Conseil National de l'Ordre des Pharmaciens de Côte d'Ivoire
Croatia	Croatian Pharmaceutical Society
Cuba	Sociedad Cubana de Ciencias Farmaceuticas
Cyprus	Cyprus Turkish Pharmacist Association
Czech Republic	Czech Pharmaceutical Society
Denmark	Danmarks Apotekerforening
	Pharmadanmark
Egypt	Pharmaceutical Society of Egypt
	Syndicate of Pharmacists in the Arab Republic of Egypt
Eritrea	Eritrean Pharmaceutical Association
Ethiopia	Ethiopian Pharmaceutical Association
Finland	Finnish Pharmacists Association
	Association of Finnish Pharmacies
	Finnish Pharmacists Society
France	Société Française de Pharmacie Clinique
	Conseil National de l'Ordre des Pharmaciens
	Syndicat National des Pharmaciens des Établissements Publics de Santé (SYNPREFH)
	Fédération des Syndicats Pharmaceutiques de France
	Association de Pharmacie Galénique Industrielle
	Union des Syndicats de Pharmaciens d'Officine
Syndicat National des Pharmaciens Praticiens Hospitaliers et Praticiens Hospitaliers Universitaires	
Germany	Algemeine Bundesvereinigung Deutscher Apothekerverbände (ABDA)
Ghana	Pharmaceutical Society of Ghana
Guinea	Conseil National de l'Ordre des Pharmaciens de Guinea
Hong Kong (SAR China)	Pharmaceutical Society of Hong Kong

Hungary	Hungarian Association of Private Pharmacists (HAPPh)
	Hungarian Society for Pharmaceutical Sciences
Iceland	Pharmaceutical Society of Iceland
India	Indian Pharmaceutical Association
Indonesia	Indonesian Pharmacists' Association
Iraq	Iraqi Pharmaceutical Association
Ireland	Pharmaceutical Society of Ireland
Israel	Pharmaceutical Association of Israel
Italy	Federazione Ordini Farmacisti Italiani
	Federfarma
Japan	Pharmaceutical Society of Japan
	Japan Pharmaceutical Association
	Academy of Pharmaceutical Science & Technology
Jordan	Jordan Pharmaceutical Association
Kenya	Pharmaceutical Society of Kenya
Korea (Rep. of)	Korean Pharmaceutical Association
	Pharmaceutical Society of Korea
Kosovo - UNMIK	Kosova Pharmaceutical Society
Kuwait	Kuwait Pharmaceutical Association
Latvia	Pharmacists' Society of Latvia
Lebanon	Ordre des Pharmaciens du Liban
Lithuania	Lithuanian Pharmaceutical Association
Luxembourg	Syndicat des Pharmaciens Luxembourgeois asbl
Macedonia	Pharmaceutical Chamber of Macedonia
Madagascar	Ordre National des Pharmaciens de Madagascar
Malaysia	Malaysian Pharmaceutical Society
Mali	Conseil National de l'Ordre des Pharmaciens du Mali
Mexico	Col. Nac. de Químicos Farmac. Biólogos México, AC
Moldova	Association of Pharmacists of Republic of Moldova (AFRM)
Mongolia	The Mongolian Pharmaceutical Association
Morocco	Le Conseil des Pharmaciens Biologistes
	Conseil Regional des Pharmaciens d'Officine du Nord
Nepal	Graduate Pharmacists' Association of Nepal (GPAN)
Netherlands	Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie (KNMP)
Nigeria	The Nigerian Association of Industrial Pharmacists
	Pharmaceutical Society of Nigeria (PSN)
Norway	Norsk Farmaceutisk Selskap
	Norges Farmaceutiske Forening
	Norges Apotekerforening
Panama	Colegio Nacional de Farmacéuticos de Panamá
Paraguay	Asociación de Químicos Farmacéuticos del Paraguay
Philippines	Philippine Pharmaceutical Association
Poland	Polish Pharmaceutical Society
Portugal	Ordem dos Farmacêuticos
	Associação Nacional das Farmácias
Rwanda	Association Rwandaise de Pharmaciens (ARPHA)
Senegal	Ordre National des Pharmaciens du Senegal
Serbia	Pharmaceutical Chamber of Serbia
	Pharmaceutical Society of Serbia (PSS)
Singapore	Pharmaceutical Society of Singapore

Slovenia	Slovensko Farmacevtsko Drustvo
Spain	SEFIG - Espanola de Farmacia Industrie Barcelona
Spain	Consejo General de Colegios Oficiales de Farmacéuticos
Sri Lanka	Pharmaceutical Society of Sri Lanka
Sudan	Sudanese Pharmacists Union
Sweden	Apoteket AB
	Sveriges Farmaceutförbund
Switzerland	Association of Swiss Pharmacists - PharmaSuisse
Thailand	Pharmaceutical Association of Thailand
Tunisia	Conseil National de l'Ordre des Pharmaciens de Tunisie
Turkey	Turkish Pharmaceutical Technology Scientists' Association
	Turkish Pharmacists Association
Uganda	Pharmaceutical Society of Uganda
United Kingdom	Academy of Pharmaceutical Sciences
	Royal Pharmaceutical Society of Great Britain
United States	American Society of Health-System Pharmacists
	American Pharmacists Association
	American Association of Pharmaceutical Scientists
Uruguay	Asociación de Química y Farmacia del Uruguay
Viet Nam	Vietnamese Pharmaceutical Association
Zambia	Pharmaceutical Society of Zambia
Zimbabwe	Pharmaceutical Society of Zimbabwe

## FIP Observer Organisations:

Pharmaceutical Group of the European Union (PGEU)

International Federation of Catholic Pharmacists

Federacion Farmaceutica Panamericana

Associação de Farmacêuticos dos Países de Língua Portuguesa (AFPLP)

The European Federation for Pharmaceutical Sciences (EUFEPS)

Federación Farmacéutica Sudamericana

## A Report from the Bureau, Executive Committee, Working Group on Public Policy, and Secretariat

### Bureau

The Bureau met on three occasions during the year in review. The first meeting was held on 24 and 25 February in Basel, Switzerland. The second Bureau meeting took place in London, UK, on 11-12 May. The third meeting was held on 31 August in Beijing, China, prior to the FIP Congress.

## Bureau Members before September 2007

<b>President*</b>	Prof. K.K. Midha, <i>Canada</i>
<b>General Secretary*</b>	Mr A.J.M. Hoek, <i>The Netherlands</i>
<b>Professional Secretary*</b>	Prof. H.R. Manasse Jr., <i>USA</i>
<b>Scientific Secretary*</b>	Dr V. P. Shah, <i>USA</i>
<b>Immediate Past President*</b>	Mr J. Parrot, <i>France</i>
<b>Chairman of the Board of Pharmaceutical Sciences</b>	Prof. D.J.A. Crommelin, <i>The Netherlands</i>
<b>Chairman of the Board of Pharmaceutical Practice</b>	Prof. P.J. Schneider, <i>USA</i>
<b>Vice Presidents:</b>	Mr J.A. Bell, <i>Australia</i>
	Dr M. Buchmann, <i>Switzerland</i>
	Ms B. Frøkjær, <i>Denmark</i>
	Prof. M. Hashida, <i>Japan</i>
	Dr M.L. Rocci, <i>USA</i>
	Prof. M. Rowland, <i>UK</i>
	Mr P.D. Sheth, <i>India</i>
	Mrs L. J. Stone, <i>UK</i>
	Prof. Th.F.J. Tromp, <i>The Netherlands</i>

\* Members of the Executive Committee

## Bureau Members after September 2007

<b>President*</b>	Prof. K.K. Midha, <i>Canada</i>
<b>General Secretary*</b>	Mr A.J.M. Hoek, <i>The Netherlands</i>
<b>Professional Secretary*</b>	Prof. H.R. Manasse Jr., <i>USA</i>
<b>Scientific Secretary*</b>	Dr V. P. Shah, <i>USA</i>
<b>Immediate Past President*</b>	Mr J. Parrot, <i>France</i>
<b>Chairman of the Board of Pharmaceutical Sciences</b>	Prof. D.J.A. Crommelin, <i>The Netherlands</i>
<b>Chairman of the Board of Pharmaceutical Practice</b>	Prof. P.J. Schneider, <i>USA</i>
<b>Vice Presidents:</b>	Mr J.A. Bell, <i>Australia</i>
	Dr M. Buchmann, <i>Switzerland</i>
	Ms B. Frøkjær, <i>Denmark</i>
	Prof. M. Hashida, <i>Japan</i>
	Dr M.L. Rocci, <i>USA</i>
	Prof. M. Rowland, <i>UK</i>
	Mr P.D. Sheth, <i>India</i>
	Mrs L. J. Stone, <i>UK</i>
	Prof. Th.F.J. Tromp, <i>The Netherlands</i>

\* Members of the Executive Committee

## Executive Committee

The Executive Committee met on six occasions in 2007: 23 February in Basel, Switzerland; 27 March in London, UK; 10 and 11 May in London, UK; 11 July in Otterlo, The Netherlands; 30 August in Beijing, People's Republic of China and 12 and 13 October in The Hague, The Netherlands.

## Council

The Council, the governing body of FIP, met on 1 September in Beijing, China. Highlights of this meeting included:

The acceptance of four new Member Organisations:

- Pharmaceutical Society of Korea\*
- Pharmaceutical Chamber of Macedonia
- Turkish Pharmaceutical Technology Scientists' Association (TUFTAD)\*
- Canadian Society for Pharmaceutical Sciences\*

The organisations marked with an \* were admitted as Predominantly Scientific Member Organisations (PSMO).

The cancellation of six Member Organisations :

- Conseil National de l'Ordre des Pharmaciens d'Alger
- Bulgarian Association of Pharmacists
- Pharmacist's Association of Belize
- Colegio Quimico Farmaceutico de Chile
- Pan-Cyprian Pharmaceutical Association
- Malta Chamber of Pharmacists

Bureau Elections:

- Ratification of Scientific Secretary of FIP for a four-year term 2007 - 2011
- Dr Vinod P. Shah from the United States

## Working Group on Public Policy

The Working Group consisted of:

Lowell Anderson, *Convenor*

John Gans

Henri Lepage

Carmen Peña

Niels Kristensen

Chui Wai Keung

No new Statements of Policy were presented nor voted on throughout 2007.

## Awards 2007

In previous years the FIP Foundation for Education and Research recognised outstanding achievements in the fields of Pharmaceutical Practice or the Pharmaceutical Sciences by making Awards. At the Bureau Meeting of 3 September 2004, it was decided that as of 2005 these Foundation awards would become FIP Awards.

## Types and Hierarchy of FIP Awards

General	Practice	Science
Honorary President		
	André Bédard Award	Høst-Madsen Medal
Honorary Member		
	Lifetime Achievement	Lifetime Achievement
Distinguished Service Award	Distinguished Practice Award	Distinguished Science Award
	FIP Fellow (FFIP)	FIP Fellow (FFIP)
	Bio-Tech Award	Bio-Tech Award

The following awards were presented in Beijing, People's Republic of China during the FIP Annual Congress:

### FIP Lifetime Achievement in the Pharmaceutical Practice Award:

Professor Dr Zoltán Vincze, *Hungary*

### Høst-Madsen Medal

Prof. Patrick Couvreur, *France*

### Distinguished Practice Award:

Mrs Jane Nicholson, *UK*

### FIP Fellows:

- Prof. S.I. (Charlie) Benrimoj, *Australia*
- Mrs Cynthia K. Brown, *USA*
- Dr John A. Gans, *USA*
- Dr Ross W. Holland, *Australia*
- Mr Howard Rice, *Israel*

11

## FIP Expands at Home and Abroad

At the very end of the 2007-2008 Annual Report period FIP opened an off-site office to represent FIP in Geneva, Switzerland. The office is headed by Mr Xuanhao Chan and will serve to increase communication and further partnerships with the World Health Organization and with FIP's partners in the World Health Professions Alliance, located in and close by the Geneva area.

In addition, FIP was pleased to welcome a new Project Coordinator, Mr Luc Besançon, to FIP Headquarters in The Hague. Luc comes to us from L'Ordre des pharmaciens in France, and FIP is very happy to have him on board.

With these new developments, FIP aims to continue the progress and development of current and future projects.





# Congress Report and Calendar



## World Congress of Pharmacy and Pharmaceutical Sciences 2007 67<sup>th</sup> International Congress of FIP Beijing, China; 31 August - 6 September

More than 3000 participants, accompanying persons, students, journalists and exhibitors attended the 67<sup>th</sup> FIP World Congress of Pharmacy and Pharmaceutical Sciences in Beijing, China. The official event was preceded by the gathering of the FIP Member Organisations at the Council Meeting.

During the Opening Ceremony the Høst Madsen award was presented to Prof. Patrick Couvreur from France. The FIP Distinguished Practice Award was presented to Mrs Jane Nicholson, UK and the Lifetime Achievement in the Pharmaceutical Practice Award to Dr Zoltan Vincze from Hungary. Furthermore FIP recognised the following individuals as FIP Fellows:  
Prof. Charlie Benrimoj, *Australia*; Mr. Howard Rice, *Israel*; Dr. Ross Holland, *USA*; Dr. John Gans, *USA* and Mrs. Cynthia Brown, *USA*.



In a similar manner as in the previous year, during the annual Congress the professional and scientific symposia were held in parallel. This enabled participants to attend all professional practice or scientific lectures without overlap.

Pre-Satellite 1, organised by the Industrial Pharmacy Section:

*Pharmaceutical Manufacturing Science & Practice*

Pre-Satellite 2, organised by the Pharmacy Information Section:

*Strategies in Medication Safety - Pharmacovigilance and Preventing Medication Errors*

Pre-Satellite 3, organised by the Community Pharmacy Section:

*Introduction to Chinese Pharmacy Practice*

Pre-Satellite 4, organised by the Community Pharmacy Section:

*Forum for Innovators in Pharmacy Practice*

The Pharmacy Practice Symposia covered important topics under the general heading of *From Anecdote to Evidence: Pharmacists helping patients make the best use of medicines:*

- Personal, cultural and social belief systems and the use of medicines
- Regulatory, manufacturing, supply-chain and quality standards issues
- Technical, scientific and evidence-based information resources about medicines
- Future issues with conventional, and complementary & alternative medicines

## Professional - Scientific Symposia

### Counterfeiting 1 and 2

The scientific programme organised the following symposia:

- Dissolution testing: A pivotal tool for development and quality of drugs
- Pharmacoepidemiology: (a) hepatitis model & (b) antibiotic resistance
- Improving Bioavailability/Bioequivalence
- Biotechnology
- Quality control for natural products
- Research in natural products
- Impact of individualized medicine in pharmaceutical care
- From knowledge to controlling; Medicinal chemistry based on chemical biology

The General Sessions covered the following topics:

- GMP & GCP
- Life long learning and continuing professional development: We have all heard the theory, what is the evidence
- Financing the healthcare
- Pharmaceuticals and the environment
- How to guarantee the best therapeutic outcome of a pharmaceutical product - the influence of a life cycle
- Antimicrobial drug resistance - the role of the pharmacy profession in tackling this emerging global health problem

- Risk communication in patient safety: To what extent can pictograms help in labeling
- Workshop: Nuclear/radiologic pharmacy
- Clinical biology in South East Asia
- Pharmaceutical distinctive features of different countries during their history
- Evidence based practice and complementary medicines: Teaching and learning by example
- Is there enough evidence for the value of pharmacists
- Clinical trials in Asia
- Customer relationships Part I and II
- Evolution of practices in clinical biology
- Nanotechnology - From science to industrial practice
- Strengthening the responsible self care of patients
- Practitioners' day - Short oral presentations Forum Part I and Part II
- Good versus bad drug information in the public domain - Can you spot the difference
- WHO/FIP Workshop: Herbal medicines: Education and training of pharmacy practitioners
- The Asian drug market - Current topics and challenges
- The challenges of diabetes in Asia
- Continuing Education Programme: From research to daily practice - Implementing family pharmacy - An innovative strategy and business model Part I and Part II
- The use of informatics to improve medication safety
- Current issues on drug and healthcare information
- Rationalising medication management for emergency response
- Responding to global and local emergencies

Young Pharmacists' and Students' Programme covered the following topics:

- Experiential learning - Bridging classroom education and pharmacy practice
- Social dimensions of developing the pharmacy profession
- Trends in community pharmacy - Debating the future of the profession: Forum for policy makers in pharmacy practice
- Medication reviews - beyond medication counseling towards service delivery
- Good manufacturing practice (GMP) & good clinical practice (GCP)

15

**Short oral presentations were also organised by some FIP Sections.**

The Welcome Reception took place on Monday evening at Jiuhua Spa and Resort where participants had the opportunity to meet representatives from the FIP Sections, Special Interest Groups and FIP Forums and to become familiar with their activities.

Six hundred and forty posters on pharmaceutical science and practice-related research were on display during four days and provided excellent opportunities for discussion and the sharing of experiences through-out the week. In addition to its scientific and professional programme, the FIP Congress once more provided the participants with memorable social events such as the Goodbye Party at the Great Wall of China, where all were captivated by the stunning view of the illuminated Great Wall and were welcomed by the famous dragon dance into the dining area where all enjoyed good food, entertainment and dancing.

## Future Congresses

### World Congress of Pharmacy and Pharmaceutical Sciences 2008

68<sup>th</sup> International Congress of FIP

Basel, Switzerland from 29 August - 4 September 2008

### World Congress of Pharmacy and Pharmaceutical Sciences 2009

69<sup>th</sup> International Congress of FIP

Istanbul, Turkey from 2 - 8 September 2009





# Board of Pharmaceutical Sciences (BPS)

## Members of the Board

Prof. Daan J.A. Crommelin, CHAIRMAN OF THE BOARD OF PHARMACEUTICAL SCIENCES, *The Netherlands*

Dr Vinod P. Shah, FIP SCIENTIFIC SECRETARY/CHAIR SIG BA/BE, *USA*

Prof. Yuichi Sugiyama, IMM. PAST CHAIRMAN BPS, *Japan*

Prof. Kamal K. Midha, FIP PRESIDENT, *Canada*

Mr Ton J.M. Hoek, FIP GENERAL SECRETARY, *The Netherlands*

Prof. Henri R. Manasse, Jr., FIP PROFESSIONAL SECRETARY, *USA*

Dr Mario Rocci, Jr., (BPS ExCo) FIP VICE PRESIDENT/CHAIR PSWC 2010, *USA*

Prof. Malcolm Rowland, (BPS ExCo) FIP VICE PRESIDENT, *UK*

Prof. Mitsuru Hashida, FIP VICE PRESIDENT/ EXPERT MEMBER PSWC 2010, *Japan*

Dr Dirk Maarten Barends, Co-CHAIR SIG BIOPHARMACEUTICS CLASSIFICATION SYSTEMS, *The Netherlands*

Prof. James Polli, Co-CHAIR SIG BIOPHARMACEUTICS CLASSIFICATION SYSTEMS, *USA*

Mrs Cynthia K. Brown, Co-CHAIR SIG DISSOLUTION, *USA*

Dr Horst-Dieter Friedel, Co-CHAIR SIG DISSOLUTION, *Germany*

Dr Anke-Hilse Maitland-van der Zee, Co-CHAIR SIG INDIVIDUALIZED MEDICINE, *The Netherlands*

Dr Majid Moridani, Co-CHAIR SIG INDIVIDUALIZED MEDICINE, *USA*

Prof. Hitoshi Sasaki, Co-CHAIR SIG INDIVIDUALIZED MEDICINE, *Japan*

Dr Nobutaka Fujii, Co-CHAIR SIG MEDICINAL CHEMISTRY / DELEGATE OF PSJ, *Japan*

Prof. Ulrike Holzgrabe, Co-CHAIR SIG MEDICINAL CHEMISTRY, *Germany*

Prof. Toshio Honda, Co-CHAIR SIG NATURAL SUBSTANCES, *Japan*

Dr Carmen Tamayo, Co-CHAIR SIG NATURAL SUBSTANCES, *USA*

Dr Siddharth J Advant, Co-CHAIR SIG PHARMACEUTICAL BIOTECHNOLOGY, *USA*

Prof. Gavin Brooks, Co-CHAIR SIG PHARMACEUTICAL BIOTECHNOLOGY, *UK*

Prof. Hideyoshi Harashima, Co-CHAIR SIG PHARMACEUTICAL BIOTECHNOLOGY/DELEGATE OF APSTJ, *Japan*

Prof. Bert Leufkens, Co-CHAIR SIG PHARMACOEPIDEMIOLOGY/ECONOMICS, *The Netherlands*

Prof. Brenda J. Waning, Co-CHAIR SIG PHARMACOEPIDEMIOLOGY/ECONOMICS, *USA*

Dr Eduardo Savio, Co-CHAIR SIG RADIOLOGIC/NUCLEAR PHARMACY, *Uruguay*

Mr Clyde N. Cole, Co-CHAIR SIG RADIOLOGIC/NUCLEAR PHARMACY, *USA*

Prof Patrick P. Deluca, DELEGATE OF AAPS, *USA*

Dr Karen Habucky, DELEGATE OF AAPS, *USA*

Mr John Lisack, Jr., DELEGATE OF AAPS, *USA*

Dr Elias Fattal, DELEGATE OF APGI, *France*

Prof. Ross A. McKinnon, DELEGATE OF APSA, *Australia*

Prof. Bill Dawson, DELEGATE OF APSGB, *UK*

Prof. Tsuneji Nagai, DELEGATE OF APSTJ, *Japan*

Ms Barb Scollick, DELEGATE OF CSPS, *Canada*

Dr In Koo Chun, DELEGATE/PRESIDENT OF PHARMACEUTICAL SOCIETY OF KOREA, *Republic Of Korea*

Prof. Tatsuhiro Irimura, DELEGATE OF PSJ, *Japan*

Prof. Jun Haginaka, DELEGATE OF PSJ, *Japan*

Prof. José Lanao, DELEGATE OF SEFIG, *Spain*

Prof. Atilla A. Hincal, DELEGATE/PRESIDENT OF TUFTAD, *Turkey*

Mr Hans H. Lindén, DELEGATE OF EUFEPS/OBSERVER, *Sweden*

Mr Ragnar Salmen, DELEGATE OF NPS/OBSERVER, *Norway*

Prof. Masahiro Hayashi, EXPERT MEMBER, *Japan*

Prof. Jin-Ding Huang, EXPERT MEMBER, *Taiwan*

Prof. Hans Junginger, EXPERT MEMBER, *Germany*

Dr Sabine Kopp, EXPERT MEMBER, *Switzerland*

Mr Ajit Singh, EXPERT MEMBER, *India*

Prof. Salomon Stavchansky, EXPERT MEMBER, *USA*

Dr Roger L. Williams, EXPERT MEMBER/BPS CHAIR OF PUBLIC POLICY COMMITTEE, *USA*

Dr Robert Bell, EXPERT MEMBER PSWC 2010, *USA*

Dr Ho-Leung Fung, EXPERT MEMBER PSWC 2010, *USA*

Prof. Geoffrey T. Tucker, EXPERT MEMBER PSWC 2010, *UK*

## A Message from the Scientific Secretary

The FIP Board of Pharmaceutical Sciences is pleased to report a highly successful year of activities and involvement on behalf of the Executive Committee, Special Interest Groups and Members alike.

### Board of Pharmaceutical Sciences

The BPS held two official meetings, the first during the FIP Congress in Beijing, China, on 2 September 2007 and the second in The Hague, The Netherlands on 5 April 2008 and an informal meeting in November 2007. Throughout the year the Board furthered its goal of establishing itself as the leading global forum for pharmaceutical scientists by organising quality scientific symposia at the FIP World Congresses, planning, organising and executing a Pharmaceutical Sciences World Congress which convened in Amsterdam, The Netherlands, April 22-25, 2007, and following through with several very successful outreach programs (Regulatory Science; Hands on Dissolution and Bioequivalence; Biotechnology and Quality workshops) in developing countries.

#### Pharmaceutical Sciences World Congress (PSWC) 2007

The Pharmaceutical Sciences World Congress 2007 was held in Amsterdam, April 22-25, 2007. It displayed cutting edge science programs in the pharmaceutical science discipline with 3 distinguished lectures, 6 keynote lectures, 36 symposia, 10 round table discussions and more than 1200 posters. It attracted 2500 scientists from 72 countries. It was a great success.

18

#### Pharmaceutical Sciences World Congress (PSWC) 2010

The next Pharmaceutical Sciences World Congress will be held in co-operation with AAPS in New Orleans, USA, November 14-18, 2010. Planning for the activities has begun. The planning committee met in The Hague on April 4 in year 2008 at FIP HQ.

#### Pharmaceutical Sciences 2020

BPS held a preliminary meeting in December 2007 to discuss Pharmaceutical Sciences 2020. A follow up meeting is planned in October 2008 in Amsterdam, The Netherlands, with about 30-40 global leaders.

#### Special Interest Groups

The BPS has 9 Special Interest Groups (SIGs), each group has two or three co-chairs representing different parts of the globe. The BPS has initiated a separate annual meeting in spring with all SIG co-chairs to invigorate the SIG activities, discuss science and harmonize all BPS science activities. SIGs also provide input in the upcoming Science program for the Annual Congress.

The BPS has historically been highly involved in the BioInternational conferences, which are held every two years and aim to discuss and resolve complex issues in bioavailability and bioequivalence (BA/BE).

These discussions are held on a FIP-BPS neutral platform with academia, industry, and regulators and aim to reach international understanding and harmonization within these specialised fields. The last Bio-International conference, focusing on the theme "Towards resolution of complex bioequivalence issues" was organized in London, October 24-26, 2005. The next Bio-International conference planned for October 22-24, 2008 in London will address "Towards Improved Harmonization in Regulating Multisource Products".

BPP-IPS and BPS have jointly initiated Quality-International Workshops, held every two years, alternatively with Bio-International Workshops in London.

One of the major activities of BPS is the outreach educational and regulatory science program. This includes 'hands-on-dissolution' workshop, regulatory bioavailability/bioequivalence workshop, biotechnology workshop and quality workshop.

The SIG on BCS has published several Biowaiver monographs of Active Pharmaceutical Ingredients (APIs) for medicines on the WHO List of Essential Drugs in the *Journal of Pharmaceutical Science*. This activity is continued. They are available on the FIP website. These monographs provide solubility and permeability information to sponsors for use in submitting their dossier to regulatory authorities for biowaiver.

The BPS has established two new SIGs (1) Medicinal Chemistry and (2) Environment and Pharmaceuticals.

### Events in Brief:

- BPS has initiated 2nd official meeting in spring to further enhance communication, discussion and dissemination of Scientific activities.
- BPS has a strategic plan that was revised and finalized in October 2005. BPS members were requested to review both FIP Strategic Plan and BPS Strategic Plan and suggest any changes to align the BPS plan with the FIP plan.
- In order to increase the interactions between and within the BPS Special Interest Groups (SIGs) and to enhance their input into BPS activities, the BPS continued their spring annual all SIGs co-chairs meeting.
- The BPS contributed to the revision of the WHO Guideline: Multisource (generic) pharmaceutical products. These guidelines are now finalized.
- FIP - BPS/AAPS Regulatory Science Workshops were held in Hanoi and HCM City, Vietnam in November 2007.
- A BA/BE regulatory science workshop was held in Istanbul, Turkey, March 17-18, 2008.
- Pharmaceutical Quality Workshop in India, February 2008.
- A vaccine workshop is planned for September 15-17, 2008, organized by EUFEPS and BPS in cooperation with AAPS.
- A pre-satellite workshop on "Special dosage form - in vitro" release is planned for October 20-21, 2008 in London.
- Bio-International Conference on "Towards improved harmonization in regulating multisource products" will be held in London, October 22-24, 2008.

- SIG Natural Products will be collaborating with WHO in developing a TCM workshop program in China, November 7-9, 2008.
- The SIG Individualized Medicine has planned a workshop with AAPS in US in November 2008. This will be the third workshop in the series going around the globe.
- Hands-on-Dissolution workshops will be held in Uruguay in November 2008.

## PSMOs

Three new PSMOs have joined FIP/BPS this year. (1) Canadian Society of Pharmaceutical Sciences (CSPS); (2) Pharmaceutical Society of Korea (PSK); and (3) Turkish Pharmaceutical Technology Scientists Association (TUFTAD).

BPS tries to interact with its PSMO members to develop workshops, symposia and other scientific activities. The BPS Chair and/or the Scientific Secretary met with AAPS, CRS, EUFEPS, PSJ, APSTJ, TUFTAD and PSK leadership separately at their annual meeting to discuss better interactions with FIP and collaboration in scientific programs.

## BPS Public Policy

BPS, through its chair is working on developing three important policies (1) Medicines for Children (2) Therapeutic Equivalence and (3) Biosimilars. The policy on Medicines for Children has been forwarded to WGPP and will be discussed in the Council in Basel, Switzerland at the FIP Congress in September 2008.

20

## FIP/BPS Awards

The BPS recognises its scientists by bestowing FIP Awards. In 2007, FIP bestowed their highest Scientific Award, Høst-Madsen Medal to Prof. Patrick Couvreur of France. In addition, recognised individuals are given FIP Fellow status to deserving candidates.

## BPS/BPP Interactions

Members of the two boards are working together to bridge the gap between science and practice. Examples of this include (1) interactions with FIP/IPS in holding joint workshops as well as symposia at annual congresses (2) translational science, how science can/will influence practice, (3) counterfeit medicine.

## Financial Status:

BPS is in a financially sound situation, and has a reserve of over Euros 100,000 to its credit from the profits of international workshops.

## Conclusions

The BPS is pleased with the accomplishments of 2007-2008, and looks forward to continued active involvement in the coming years whereby the current Strategic Plan will be used as a guiding document.

**Dr Vinod P. Shah**  
SCIENTIFIC SECRETARY  
May 1, 2008.

## The FIP Board of Pharmaceutical Sciences Special Interest Groups

The pharmaceutical sciences have been at the foundation of the International Pharmaceutical Federation (FIP) since its conception almost 100 years ago, and throughout this time various specialised fields of pharmacy and science have played an integral role in the success and evolution of the Federation. Now tended by the Board of Pharmaceutical Sciences, this branch of the Federation encompasses seven Special Interest Groups guided by the following mission:

*The mission of the BPS is to establish and maintain itself as the leading forum for the advancement of pharmaceutical sciences and technology worldwide by building strong alliances which foster the sharing of knowledge and facilitate global discovery, development, manufacture, and utilization of high quality, safe and effective medicines.*

The BPS Special Interest Groups serve the distinct needs of those involved in very specific and dedicated branches of the pharmaceutical sciences. Through their work and initiatives, global networks of specialists have been established, fostering communication and the sharing of knowledge within and between pharmaceutical scientists the world over.

21

### The BPS Special Interest Groups (SIGs)

#### **SIG Bioavailability/Bioequivalence (BA/BE)**

In 1994, BPS established a Special Interest Group (SIG) in the area of bioavailability/bioequivalence (BA/BE) to address controversial and complex issues in the area of BE. One of the important activities of SIG BA/BE has been holding Bio-International Conferences. These conferences are held to discuss and resolve complex issues in BA/BE and to reach international understanding and harmonization. Since last few years, these Bio-International Conferences are held in London in co-sponsorship with Royal Pharmaceutical Society of Great Britain. Next such conference is planned for October 2008.

Initially, this SIG had two working groups (WG), Dissolution WG and Biopharmaceutics Classification System WG. These two WGs have now been developed into SIGs to more attentively serve the needs of pharmaceutical sciences working in these highly focused areas.

**Co-Chair:** Dr Vinod P. Shah.

### SIG Biopharmaceutics Classification System

This SIG aims to provide an independent platform for scientific discussions between academia, industry and regulators on the possibilities and the limitations of biowaivers for in vivo bioequivalence studies based on Biopharmaceutics Classification System (BCS). The group publishes biowaiver monographs for Active Pharmaceutical Ingredient (APIs) of the World Health Organization (WHO) List of Essential Medicines.

**Co-chairs:** Dr Dirk Maarten Barends  
Dr James Polli

### SIG In vitro Testing

The major activity of the group has been to plan and organise workshops in the area of dissolution/in vitro release, develop dissolution guidelines, resolve complex issues related to dissolution and attempt to standardize global "dissolution tests". Previous to their establishment as a SIG the former working group developed (1) "FIP Guidelines for Dissolution Testing of Solid Oral Products" and (2) "FIP/AAPS guidelines for dissolution/in vitro release testing of novel/special dosage forms. Workshops were also established with the WHO to provide proper training for and understanding of dissolution tests to scientists in developing countries. One of the major outreach activities of this group is Hands-on-Dissolution workshop, to train and educate people on how to perform the important test of dissolution. These workshops have been held globally in various countries.

**Co-chairs:** Mrs Cynthia K. Brown  
Dr Horst-Dieter Friedel

### SIG Individualized Medicine

Individualized medicine is an area which has of late attracted much attention and many influential researchers. As this up-and-coming area makes full use of the latest in medical and scientific developments, individualized medicine will be an important domain in the medical spotlight in many years to come. Its potential to influence current and new treatments and treatment protocols will expand throughout drug design and pharmaceutical care, making individualized medicines a major contributor to the pharmaceutical science and practice process from start to finish, and as such is key area of focus for FIP. The SIG held a very successful workshop in Tokyo, Japan in February 2006 and in The Netherlands in November 2007.

**Co-chairs:** Prof. Hitoshi Sasaki  
Dr Anke-Hilse Maitland-van der Zee  
Dr Majid Moridani

### SIG Natural Substances

In 2003 a Special Interest Group on Natural Substances (formerly Natural Products) was established within the FIP Board of Pharmaceutical Sciences. Although medicinal plants are of continuing interest as a source of lead molecules and also as phytopharmaceuticals (especially those commonly called 'herbal remedies'), it is recognized that there is much research interest in substances and compounds from other parts of the biosphere.

The aims of the group are to promote the pharmaceutical sciences relevant to the study of natural substances, educate pharmacists in research developments related to drug discovery from natural sources and in the pharmacology and interactions of natural extracts used in pharmacies, and to

disseminate novel findings related to the potential and realised use of compounds and extracts in pharmacy, especially from a cross-cultural point of view.

**Co-chairs:** Prof. Toshio Honda  
Dr Carmen Tamayo

### **SIG Pharmaceutical Biotechnology**

The SIG Pharmaceutical Biotechnology was formed in 1994 to provide a worldwide, neutral and independent platform for discussions on biotechnological issues related to the pharmaceutical sciences. The two areas of primary focus are worldwide harmonisation of regulatory regulations for biotech products, seen as a major goal of the SIG, and bridging the educational gap between biotechnologists and "classical" pharmaceutical scientists, formerly two separate and unconnected groups under the Pharmaceutical Biotechnology umbrella.

The major aim is to advance an understanding of and stimulate progress in Pharmaceutical Biotechnology through workshops, conferences and meetings both within and outside of the FIP activities. A successful workshop on Gene Delivery was organized by this SIG in Japan in 2006.

**Co-chairs:** Prof. Gavin Brooks  
Prof. Hideyoshi Harashima  
Dr Siddhart Advant

### **SIG Pharmacoepidemiology and Pharmacoeconomics**

The SIG Pharmacoepidemiology and Pharmacoeconomic is primarily concerned with what the role and effect of medicines after their delivery for patient use, subsequent to extensive pre-marketing pharmaceutical and clinical research. Keeping track with the course of events (both clinical and economical) connected to a new drug after marketing authorization is granted is a field of growing interest among pharmaceutical scientists, practitioners and policy makers. Ensuring patient safety, risk management and cost-effectiveness in the drug use system are at the top of the public health priority chart, and pharmacists and pharmaceutical scientists are essential players in the development and outcome of these issues.

Through various FIP events and activities this SIG is in place to, amongst other things, stimulate research in pharmacoepidemiology and -economics; to foster communication between scientists, practitioners, regulators and policy makers; to develop and promote scientific standards for epidemiology and economic product evaluations; and to follow the outcome of medicines use on a population level.

**Co-chairs:** Prof. Bert Leufkens  
Prof. Brenda J. Waning

### **SIG Radiologic and Nuclear Pharmacy**

The SIG Radiologic/Nuclear Pharmacy was founded in 1997 to provide an international venue for Radiologic and Nuclear Pharmacy scientists and practitioners. The SIG supports the advancement of healthcare through the promotion of emerging scientific findings in the practice of pharmacy, support of the development of pharmacy services and by providing a forum of expert opinion to promote harmonization of inter-professional disciplines worldwide.

Specific goals of the SIG include the harmonization of educational methodologies and practice guidelines

and requirements to meet competency levels for pharmacists in radiologic/nuclear pharmacy and to facilitate the development of radiologic/nuclear pharmacy services in countries that are underserved by pharmacists.

**Co-chairs:** Dr Clyde N. Cole  
Dr Eduardo Savio

#### **SIG Medicinal Chemistry**

Medicinal Chemistry is one of the important disciplines in drug discovery and development area. BPS has established this new SIG this year to fill the need of pharmaceutical scientists. The SIG is planning a standalone workshop in the field in 2008.

Co-chairs: Dr Ulrike Holzgrabe

#### **SIG Environment and Pharmaceuticals**

Many kinds of chemicals including pharmaceuticals having carcinogenic and endocrine disrupting activity are released in the environment. These pollutants threaten healthy human life. This type of environmental concern is very important for both researchers and pharmacists. The new SIG "Environmenta and Pharmaceuticals" will discuss their analysis and countermeasure and will propose an action plan to reduce the diseases caused by environmental pollution.

Co-chairs: Dr Kazuichi Hayakawa  
Dr Sorensen

The Special Interest Groups of the FIP Board of Pharmaceutical Sciences are at the cutting edge of all that is shaping the world of pharmaceutical sciences and research, and in turn medicines, their effectiveness and the overall health of patients.



# Board of Pharmaceutical Practice (BPP)

At the core of a successful membership organisation is the willingness of its members to volunteer for assisting the organisation to meet its mission and goals. This notion is well exemplified in the Board of Pharmaceutical Practice. Through its nine Sections, voluntary leaders and participants assure service to the members and also move forward their respective agendas and the overall directions of the Board. While each of the Sections has taken different approaches to work with their members and/or engage in outreach activities, the impact of Section work is far-reaching around the globe. And working within the Board's Incentive Policies, there is a continuous emphasis on member communication, involvement and outreach.

## Members of the Board

Philip J. Schneider, CHAIRMAN OF THE BOARD OF PHARMACEUTICAL PRACTICE, <i>USA</i>	Martine Chauvé, PRESIDENT -FIP COMMUNITY PHARMACY SECTION, <i>France</i>
Henri R. Manasse, Jr. ,FIP PROFESSIONAL SECRETARY, <i>USA</i>	Eeva Kirsti Teräsalmi, SECRETARY -FIP COMMUNITY PHARMACY SECTION, <i>Finland</i>
Kamal K. Midha, FIP PRESIDENT, <i>Canada</i>	Andrew Lofts Gray, PRESIDENT - FIP HOSPITAL PHARMACY SECTION, <i>South Africa</i>
Ton J.M. Hoek, FIP GENERAL SECRETARY, <i>The Netherlands</i>	Stephen J. Curtis, SECRETARY - FIP HOSPITAL PHARMACY SECTION, <i>UK</i>
Vinod P. Shah, FIP SCIENTIFIC SECRETARY, <i>USA</i>	Tom Sam, PRESIDENT -FIP INDUSTRIAL PHARMACY SECTION, <i>The Netherlands</i>
Th. (Dick) F.J. Tromp, (BPP ExCo) IMM. PAST CHAIRMAN BPP/FIP VICE PRESIDENT, <i>The Netherlands</i>	Henriette Sophie Jansen, SECRETARY -FIP INDUSTRIAL PHARMACY SECTION, <i>The Netherlands</i>
Bente Frøkjær, FIP VICE PRESIDENT, <i>Denmark</i>	Frans van de Vaart, PRESIDENT -FIP LAB. & MED. CONTROL SERV. SECTION, <i>The Netherlands</i>
Claire Anderson, BPP ExCo, <i>UK</i>	Antonio J. Bica , SECRETARY -FIP LAB. & MED. CONTROL SERV. SECTION, <i>Portugal</i>
Han de Gier, (BPP ExCo) PRESIDENT -FIP PHARMACY INFORMATION SECTION, <i>The Netherlands</i>	Régis Vaillancourt, PRESIDENT - MILITARY & EMERGENCY PHARMACY SECTION, <i>Canada</i>
Agathe Wehrli, SECRETARY -FIP PHARMACY INFORMATION SECTION, <i>Switzerland</i>	Jane Dawson, SECRETARY - MILITARY & EMERGENCY PHARMACY SECTION, <i>New Zealand</i>
Jennifer Lillian Marriott, PRESIDENT -FIP ACADEMIC PHARMACY SECTION, <i>Australia</i>	Martin Schulz, CHAIRMAN BPP PROGRAMME COMMITTEE / BPP EXPERT MEMBER, <i>Germany</i>
Wafa Y. Dahdal, SECRETARY -FIP ACADEMIC PHARMACY SECTION, <i>USA</i>	Dominique Jordan, VICE PRESIDENT -FIP COMMUNITY PHARMACY SECTION, <i>Switzerland</i>
Marion Schaefer, PRESIDENT -FIP ADMINISTRATIVE PHARMACY SECTION, <i>Germany</i>	Karen Mc Gill, OBSERVER, IPSF PRESIDENT 07-08, <i>The Netherlands</i>
Marina Altgracia, SECRETARY -FIP ADMINISTRATIVE PHARMACY SECTION, <i>Mexico</i>	Gisselle Gallego, OBSERVER, YPG CHAIR, <i>Australia</i>
Bernard Poggi, PRESIDENT -FIP CLINICAL BIOLOGY SECTION, <i>France</i>	
Alain Mazaleyrat, SECRETARY -FIP CLINICAL BIOLOGY SECTION, <i>France</i>	

## Board of Pharmaceutical Practice Mission and Strategic Plan

Following several years of preparatory work, the Board has concluded the creation of a Mission and Strategic Plan. The Mission is stated as follows:

The Mission of the Board of Pharmaceutical Practice of the International Pharmaceutical Federation is to define, promote and realize an envisioned future for global pharmacy in all practice settings to improve the health of patients from the use of medicines worldwide through the contribution of pharmacists.

In furthering this Mission, the Board has adopted the following goals:

- Putting patients first in all of our work and at the center of our practice, considering the patient as our partner
- Fostering the transformation of pharmacy practice in all settings by discovering ways to improve the rational, safe and cost-effective use of medicines and the outcomes from their use
- Helping to create a workforce model that focuses on assuring both appropriate competence and adequate supply to improve the rational, safe and cost-effective use of medicines and the outcomes from their use
- Helping to develop reimbursement models that will provide the necessary financial support for the effective management of both the medicine supply chain and provision of direct patient care services

Several strategies have been put in place or are under current consideration in achieving these goals. These include a focus on: partnership with patients, enhancing pharmacy practice, applying evidence-based practices, assuring competency, assuring a sufficient workforce and creating better financial models. Specific strategic initiatives have been articulated for each of these strategies. Readers of this Report may wish to obtain a copy of the 2006-2010 BPP Mission and Strategic Plan at [www.fip.org](http://www.fip.org) or by corresponding with the FIP headquarters staff.

The Board desires to keep the plan as a living document and hence, has committed itself to reviewing the plan and revising the plan as circumstances may dictate. For now, each of the Sections is developing their own strategies for embracing and empowering the plan with their members and Section activities.

## Program Committee and Working Groups

Under the able leadership of Prof. Martin Schulz, the Program Committee is responsible to the Professional Secretary for the creation of the theme and program of the Annual Congress. The Committee works especially hard to consider the global developments of pharmacy practice, identifies issues and areas of interest and then creates, with the recommendations coming from members associations and the Bureau, a relevant, contemporary and timely program for the Congress. Moreover, it assures the quality of the programming through the creation of objectives and guidelines for speakers. It works diligently to select speakers who are experts in their respective fields and who can present within the quality framework required for program accreditation. Planning is now being finalized for the program in Istanbul and solicitations have gone out for program theme recommendations for the annual congress in Lisbon in 2010.

In addition to the work of the Sections, the work of the Board is augmented by Working Groups. We

have specifically addressed critical issues in the profession of pharmacy through the appointment of Working Groups whose members are experts in the field.

At the request of the Bureau, the Board of Pharmaceutical Practice has created a Working Group on the creation of a reference paper that will propose updating the Good Pharmacy Practice Standards approved by the Council in 1993. A revised version of this document was later approved in 1997. Much has evolved in pharmacy practice since that time and hence, the undertaking of this Working Group is quite important. Under the co-chairmanship of Dr. Dick Tromp and Prof. Henri Manasse, this Working Group has had two face-to-face meetings. Specific areas for updating in patient care practice have been identified and current work is elaborating these areas. The product of this Working Group will be a reference paper that will then be used by the Working Group on Public Policy. The latter will ultimately present its recommendations for updated Good Pharmacy Practice Standards at a forthcoming meeting of the Council.

The Working Group on Patient Safety, chaired by Professor Marion Schaefer, concluded its work this past year through the development of an extensive Report. This Report was accepted by the Board and has been subsequently reviewed by the World Health Organization (WHO). Presently it is being prepared for publication and wide distribution. The findings and recommendations of the Working Group will be helpful to our member organizations and individual members as the important issue of patient safety is addressed in our profession.

The Working Group on Collaborative Practice, co-chaired by Dr. Jill Martin and Mr. David Pruce, has just concluded its work. A Final Report is presently in development. This Group's finding and recommendations centered on the issue of pharmacist prescribing and collaborative practice between pharmacists, physicians and nurses. An important contemporary issue in the provision of health care services, further advancement of collaborative practice roles of pharmacists is addressed in the Report. The Board has heard an oral report at its March, 2008 meeting and had an extensive discussion around the major precepts presented. The Report will be finalized and widely distributed within our profession. The Board hopes to further discuss the Report with our colleague member organizations in the professions of medicine and nursing in the upcoming year.

Two additional Working Groups have been appointed and are currently at work. These include: the Working Group on Pharmacy Workforce, co-chaired by Professor Claire Anderson and Professor Marion Schaefer and the Working Group on Economic Models, chaired by Professor Cecilia Bernsten. The Working Group on Pharmacy Workforce is addressing the current state of the global pharmacy workforce (from technicians, front-line practitioners and pharmacy specialists), the needs and demands for the present and future and the policy ramifications of current and future workforce policy in pharmacy. The Working Group on Economic Models is studying current payment models in global pharmacy and analyzing their utility and effectiveness. This Working Group will also study innovative models of payment especially those that recognize the professional services and added-value of pharmacists to the management of drug therapy.

While the Board's strategic plan also addresses the need of the profession to partner with patients, this area of the plan still needs further study and explicit direction. Discussions have been held with the International Association of Patient Organizations (IAPO) and several disease-specific patient organizations. Over the course of the next months, the Executive Committee of the Board will be setting a more specific direction for this area of the Board's plan.

## The Sections

Each of the Sections within the Board of Pharmaceutical Practice has focused on several elements of the Incentive Plan previously instituted. This plan focuses on growing membership, extending visible initiatives and becoming more widely known in their work and directions. Specific financial incentives are helping the Sections to provide funding for important Section work.

Of specific note this year is the planned consensus conference of the Hospital Pharmacy Section on a "Global Future for Hospital Pharmacy." This conference is bringing together delegates from around the world to create a vision for the future of global hospital pharmacy. Much work has gone into the planning, financing and execution of the Conference. Conference Proceedings will be published so that all members and member organizations can read the consensus statements developed by the delegates.

Also of particular note this year has been the extensive number of training programs offered around the world by the Industrial Pharmacy Section. These efforts have focused on improvement of manufacturing processes, government regulatory development for manufacturing and quality assurance programs around drug manufacturing. Practitioners working in this sector of the profession have benefited extensively from these offerings.

Several others of the Board's Sections are presently engaged in creating Strategic Plans for their own Sections. These include the Academic Pharmacy, Community Pharmacy and Administrative Pharmacy sections. These Sections are explicitly focusing on expanding their influence and targeting specific initiatives for growing the size and scope of Section work.

28

The Military and Emergency Pharmacy Section continues to work on two major projects: the overall development, testing and application of pictograms related to appropriate use of medications and a focused project on pictograms to be used with asthmatic children for proper medication delivery for this disease. The Section also continues to communicate globally on matters of current and future relevance to its members.

The Sections of Clinical Biology and Laboratory and Medicinal Control Services have both focused on expanding their communication efforts and studying future developments in their respective fields. As science, technologies and regulatory areas expand globally; these Sections are directing their attention to strategic needs of their members.

The Pharmacy Information Section continues to engage its members in the expanding technologies of information services and appropriateness of drug information for clinical decision-making. Of special interest of the Section has been the utility of drug information by patients.

These short recollections of Section activities provide the reader with a sense of the activities and involvement of these components of the Board. The Section officers, executive committees and individual members add to the dynamic discussions of the Board at its two face-to-face meetings (at the Annual Congress and March of each year) and continuous electronic information exchange.

## Acknowledgements

In closing this Report, I would like to especially acknowledge several individuals for their leadership and work in assuring that the Board and its respective Sections continue to progress and have an impact in the International Pharmaceutical Federation. First, Professor Philip Schneider has ably and enthusiastically chaired the Board and the Executive Committee. He has been assisted in his work by a very capable Executive Committee composed of Prof. Han de Gier, Prof. Claire Anderson, Dr. Dick Tromp and Prof. Henri Manasse. Each of the Section Chairs and Secretaries also deserve recognition for their leadership and hard work. All of the chairs and volunteers serving on the Program Committee and the Working Groups are also acknowledged for their tremendous contributions to the work and influence of the Board. The able assistance of FIP staff including Ton Hoek, Xuan Hao Chan, Luc Besancon and Paula Cohen is also appreciated and acknowledged.

It continues to be my honor and privilege to serve as the Board's Professional Secretary. In that role I also appreciate the capacity to serve on the FIP Bureau and Executive Committee.

Respectfully submitted,

Henri R. Manasse, Jr., Ph.D., Sc.D.  
PROFESSIONAL SECRETARY

## Academic Pharmacy Section (AS)

29

### Overview

The Academic Pharmacy Section aims to attract members of the worldwide community of Academic Pharmacy to discuss issues of interest to educators with the aim of improving educational standards in order to maintain and improve pharmacy practice.

Changes to the Statutes of the Academic Pharmacy Section (AS) were passed at the FIP Council meeting in Beijing. These changes bring the statutes into line with those of other sections. The major change that impacted on the operation of the Section was the increase in the term of office of the President from two years to four years. This will enable the AS to develop a strategic plan to move the section forward, increase membership and to make the education sessions at the Annual FIP Congress relevant to members by presenting important issues for discussion that are germane to the needs of academics worldwide. The longer term of office will also enable the executive to develop some ongoing projects of value to the Academic Section, FIP and the profession.

A new Executive was elected at the 2007 Congress in Beijing, with representation from Europe, Asia, Africa, Scandinavia, the Americas and Australasia. Prof Claire Anderson remains as Past-President to provide guidance for continued development of the Section. The new Board has a good mixture of younger and older members that will hopefully guarantee the continued growth of the section. It is hoped that the broad representation of members on the Board will enable the section to increase its relevance for members, develop appropriate projects and to develop its membership.

## Number of Members (as of 1 March 2008)

Information provided by FIP headquarters indicates that membership of the Academic Section comprises: 412 total members, 339 active members, 73 non-active members.

Section financial records indicate that financial membership of the section at December 2007 was comprised of 209 full members and 16 student members.

## Executive Committee (as of 1 March 2008)

Dr Jennifer Marriott, <i>Australia</i> Jennifer.Marriott@vcp.monash.edu.au	PRESIDENT
Prof. Claire Anderson, <i>UK</i> claire.Anderson@Nottingham.ac.uk	IMMEDIATE PAST PRESIDENT
Dr Vimal Kishore, <i>USA</i> vkishore@xula.edu	TREASURER
Dr Wafa Y Dahdal, <i>USA</i> wdahda@midwestern.edu	GENERAL SECRETARY
Dr Ronnie Hansson, <i>Sweden</i> Ronnie.Hansson@farmbio.uu.se	VICE PRESIDENT
Dr Catherine Duggan, <i>UK</i> catherine.duggan@pharmacy.ac.uk	EDITOR
Mr Mike Rouse, <i>USA</i> mrouse@acpe-accredit.org	BOARD MEMBER
Miss Nilima Shrestha, <i>Nepal</i> nilima@ku.edu.np	BOARD MEMBER
Dr Tabitha Ndung'u, <i>Kenya</i> Nyamb2@yahoo.com	BOARD MEMBER
Dr Sandra Fábregas, <i>Puerto Rico</i> sfabregas@rcm.upr.edu	BOARD MEMBER
Miss Katja Hakkarainen, <i>Finland</i> katja.hakkarainen@helsinki.fi	BOARD MEMBER
Mr Suresh Panthee Chairperson of Pharmacy Education, International Pharmaceutical Students' Federation 2007-08 supanthee@gmail.com or education@ipsf.org	HONORARY MEMBER

## Strategic Plan

The vision of the Academic Section is to contribute to improved pharmacy educational standards worldwide. To achieve this vision, issues of relevance to the academic pharmacy community must be explored and debated in an open forum such as at FIP Congress meetings and projects that contribute to improvement of pharmacy education must be undertaken and implemented. The nexus between science and practice continues to be an important issue for pharmacy education worldwide and mechanisms for exploring and strengthening this bridge will be developed.

As a newly elected Committee we will consult with members to:

- determine the barriers to membership of the FIP Academic Section;
- determine the current issues of interest to pharmacy academics;
- determine the level of interest in a one-day pre-conference symposia to discuss educational issues.

This will enable the development of a strategic plan with the goal of maintaining the focus of the Section and the relevance of the congress symposia with the outcome that the overall standard of pharmacy education worldwide can be improved, leading to an increase in professional standards and membership. A range of projects will be undertaken that are aimed at achieving AS goals of addressing the needs of academic members and increasing educational standards worldwide into the future with a particular focus on developing countries. One project that could be co-ordinated jointly with Pharmabridge, is development of a web portal to share information and teaching materials between academics with a mechanism for up-dating information has been proposed for 2008-09 development.

## Congress Activities

### 67<sup>TH</sup> FIP CONGRESS BEIJING, CHINA, 2007, activities presented

ACTIVITY	TITLE	CHAIR, if applicable
Symposium	Life long learning and continuing professional development: we have all heard the theory, what is the evidence?	Prof. Claire Anderson, University of Nottingham, United Kingdom
Symposium	Experiential learning - Bridging classroom education and pharmacy practice	Jennifer Archer, University of Manchester, United Kingdom and Audrey Clarissa, International Pharmaceutical Students' Federation, Indonesia
Symposium	Evidence based practice and complementary medicines: teaching and learning by example	Prof. Gary Smith, University of Maryland, USA
Oral Presentations	Short Oral Presentations	Ronnie Hansson, Uppsala University, Sweden
Poster Presentations		
Section Business Meeting		
Section Dinner		

## 68<sup>TH</sup> FIP CONGRESS BASEL, SWITZERLAND, 2008, activities planned

ACTIVITY	TITLE	CHAIR, if applicable
Symposium	Life long learning and continuing professional development: we have all heard the theory, what is the evidence?	Prof. Claire Anderson, University of Nottingham, United Kingdom
Symposium	Experiential learning - Bridging classroom education and pharmacy practice	Ms Jennifer Archer, University of Manchester, United Kingdom and Audrey Clarissa, International Pharmaceutical Students' Federation, Indonesia
Symposium	Evidence based practice and complementary medicines: teaching and learning by example	Prof. Gary Smith, University of Maryland, USA
Oral Presentations	Short Oral Presentations	Mr Ronnie Hansson, Uppsala University, Sweden
Poster Presentations		
Section Business Meeting		
Section Dinner		

### Communication

#### NEWSLETTERS

Four Newsletters were circulated to Members of the Academic Section and BPP executive via email. Each newsletter contained an Editorial, a report on the previous congress, information on the upcoming congress including AS symposia, information concerning the changes to the AS Statutes, election information and notices of conferences and other events of interest to members of the section.

#### CONGRESS BOOKLET

A congress booklet was produced for distribution at the congress to AS members and other interested persons. The Congress booklet contained information on the AS symposia, abstracts of the oral presentations and posters and the Agenda for the Business meeting.

### Internal/External Collaboration

The Section is conducting a Symposium at the Basel Congress in collaboration with the Industrial Pharmacy Section. This half-day session will discuss the educational needs of the pharmaceutical industry and review the extent to which pharmacy undergraduate and postgraduate courses meet this need. The discussion will take into account the many demands on the teaching content of the pharmacy degree and the value of maintaining a strong science base in the pharmacists' education and training.

The Chairperson of Pharmacy Education, International Pharmaceutical Students' Federation 2007-08 - Suresh Panthee, has been invited to join the Academic Section Board as an ex-officio member. It is anticipated that this will enable closer links to be formed between the two groups.

The second FIP Pharmacy Education Taskforce was held in Beijing. This was attended by key stakeholders who reached agreement on a three year Action Plan to facilitate global developments in Pharmacy Education.

The section also has representation on the International Forum for Quality Assurance of Pharmacy Education at which the final draft of the document "A Global Framework for Quality Assurance of Pharmacy Education" was presented for discussion. The convener of this forum, Mr Mike Rouse, is now a member of the AS Section Board.

The section also maintains its links with Pharmabridge.

## Administrative Pharmacy Section (APS)

### Overview

The Administrative Pharmacy Section once again had a very productive and successful year. The Section continues to be vital, employing several task forces and working groups. The APS Executive Committee (ExCo) contributed greatly to the session program planning for the last FIP Congress in Beijing as well as for the upcoming Congress in Basel. The ExCo is again fortunate to be comprised of individuals representing most geographic areas and an interesting variety of employment affiliations, including government, academia, professional societies and patient care practice.

### Members

According to the FIP Secretariat, the number of members of the Administrative Pharmacy Section during the period represented in this Annual Report is 224 members.

### Executive Committee

Marion Schaefer, <i>Germany</i>	PRESIDENT
João L. Carapinha, <i>South Africa</i>	VICE-PRESIDENT
Marina Altagracia Martinez, <i>Mexico</i>	SECRETARY
Ann Lewis, <i>UK</i>	TREASURER
Albert I Wertheimer, <i>USA</i>	PAST PRESIDENT
Cecilia B Bernsten, <i>Sweden</i>	
Inka Puumalainen, <i>Finland</i>	
Yves Gariépy, <i>Canada</i>	
Lenka Práznovcová, <i>Czech Republic</i>	
Soo Ja Nam, <i>Korea</i>	
Mei-Ling Hsiao, <i>Taiwan</i>	

## Section & Membership Promotion

- Involving section members into the discussion about section issues via the newsletters
- Encouraging members by e-mail to submit abstracts for the Basel conference
- Continuous communication with EXCO members to encourage membership solicitation.
- Including a membership solicitation form in the section newsletter
- Participating in FIP website, and booths at the annual congress
- Extending the membership committee for another year

## Regular Publications & Communications Network

- Marina Altagracia has taken over the responsibility for the newsletters and coordinates all efforts with high commitment
- Four section newsletters were published and distributed electronically and put on the FIP website in 2007. The first issue of 2008 is shortly to be released
- Regular Reviews of WHO drafts as well as other papers of interest
- Section secretary communicates regularly with Exco members
- E-mail discussion about the agenda of a meeting of Exco officers in March 08 in TheHague

## On-Going Projects and Working Groups

- The Comparative International Drug Policy Study continues with assistance from the WHO and from FIP staff, so far 17 countries have responded, 11 countries have submitted incomplete data. Several reminders and a letter of encouragement have been sent out to FIP member organizations.
- In October 2007 a project team was set up in close cooperation with the Young Pharmacists Group.
- An online questionnaire was put on the FIP website. Versions in English and French are already available, those in French, Arabic and Portuguese will follow soon.
- Liaison with Pharmaco-Epidemiology SIG continues

## Participation in FIP, BPP and WHO Projects

- The section and its officers were involved in several BPP working groups: Counterfeits (Marion Schaefer, member), Patient safety (Marion Schaefer, chair), Pharmaceutical workforce (Marion Schaefer, co-chair), Reimbursement (Cecilia Bernsten, chair and Yves Gariepy, member)

## Communication with and to Other Sections

- Discussions at BPP and FIP meetings
- Share experiences and problems/solutions at Council meetings and informally via correspondence and through e-mail

- Development and Joint Sponsorship of sessions at the annual congress.
- Sharing our section newsletter with the officers of other sections

## Clinical Biology Section (CBS)

The main objective of the CBS is "to study and maintain the development and the protection of the scientific and professional interests of all Pharmacists engaged in Clinical Biology". The CBS groups pharmacists who are experts in the different fields of clinical laboratory medicine (clinical biochemistry, immunology, biological hematology, parasitology, microbiology, molecular biology and genetics), and encourages them to participate in the diagnosis of diseases together with physicians. The Section is also involved in the new development of biotechnology (ie pharmacogenomic, nanotechnologies etc).

### Number of Members (as of 1 March 2008)

Last figure from the FIP headquarters 65 members.

### Executive Committee (as of 1 March 2008)

Dr Bernard Poggi, <i>France</i> bernard.poggi@chu-lyon.fr	PRESIDENT
Alain Mazaleyrat, <i>France</i> mazaleyrat@clinique-pasteur-toulouse.fr	SECRETARY
Prof. Layachi Chabraoui, <i>Morocco</i>	VICE PRESIDENT
Prof. Genevieve Durand, <i>France</i>	VICE PRESIDENT
Ms Sonia Faria - <i>Portugal</i>	VICE PRESIDENT
Prof. Jun Okuda, <i>Japan</i>	VICE PRESIDENT
Prof. Francois Trivin, <i>France</i>	VICE PRESIDENT

### Strategic Plan

<p>Increase CBS membership, increase involvement in FIP activities</p>	<ul style="list-style-type: none"> <li>• Leaflet made for members in relation with the FIP congress;</li> <li>• Presence at the showcase + leaflet on advantages to be a member of the CBS;</li> <li>• Increase communication of the CBS with members</li> <li>• Creation of a section E-mail in order to ask question to the CBS officers</li> <li>• Links from FIP CBS Section to E-mail section</li> <li>• Continuous update of the CBS web site (part of the FIP general web site)</li> <li>• All activities and presentation of last congresses are presented in the newsletters of the section</li> </ul>
--	---

Increase CBS membership, increase involvement in FIP activities	<ul style="list-style-type: none"> <li>Organize workshops and symposia in countries where pharmacists are engaged in clinical biology, in collaboration with other associations</li> <li>Study Clinical biology practice in Europe in order to update</li> </ul>
Expand the role of the pharmacist	<ul style="list-style-type: none"> <li>Establish a Special document (from CBS) with conferences of interest for CBS members in each FIP general Congress</li> <li>Organize workshops in some countries in association with IFCC; in 2007, 2 workshops were organised with IFCC/EFCC in Europe (Belgium and France)</li> <li>Promote Clinical biology as a new professional opportunity for pharmacists</li> </ul>
Raise professional standards and develop and expand CPD	<ul style="list-style-type: none"> <li>Follow and active participation of the work of EC4 and the new curriculum published for Clinical Biologist in the countries of UE, with the CBE (Confédération des Biologistes Européens, Président : J.P Molgatini)</li> <li>We begin a study on quality of clinical biology practice in different countries of UE.</li> </ul>

## Congress Activities

36

### 67<sup>TH</sup> FIP CONGRESS BEIJING, CHINA, 2007, activities presented

ACTIVITY	TITLE	CHAIR, if applicable
Symposium	Joint session FIP - IFCC: CLINICAL BIOLOGY IN SOUTH-EAST ASIA	Prof. F. TRIVIN (Tours - France)
Symposium	EVOLUTION OF PRACTICES IN CLINICAL BIOLOGY	Dr B. POGGI (Lyon - France)
CBS Bureau meeting		
Site Visit	Visit of a clinical laboratory medicine	
Section Dinner	TING LI GUAN - Clinical Biology & LMCS dinner	
Showcase	Poster presentation of the CBS and presentation of a leaflet presenting the CBS	

## 68<sup>TH</sup> FIP CONGRESS BASEL, SWITZERLAND, 2008, activities planned

ACTIVITY	TITLE	CHAIR, if applicable
Site Visit	Visit of a clinical medicine laboratory in BASEL	
Symposium	Joint session FIP - IFCC: CLINICAL BIOLOGY IN European Countries	Prof. G. DURAND (Paris - France) and TBA (Switzerland)
Symposium	COOPERATION BETWEEN CLINICAL BIOLOGISTS, PHARMACISTS AND PHYSICIANS FOR THE BENEFIT OF PATIENTS CBS/CPS/LMCS JOINT SYMPOSIUM	Dr B. POGGI (Lyon - France)
Section Dinner	CBS and LMCS section diner	

### Communications

Four newsletters are sent to all members by e-mail. They are also placed on the FIP web site within the CBS pages for those who would like to download the electronic form.

The newsletters focus on the activities of the section (FIP congress, section program, summary of the interventions made, major developments at the CBS, information to members on other congresses in the field of clinical biology and developments around the world) and important information on accreditation guidance for clinical Laboratories in European countries and in other parts of the world.

37

### Internal/External Collaboration

Collaboration with other sections:

- Joint symposium CBS/LMCS/CPS in Basel
- Joint section diner CBS/LMCS, each year since 2003.

External collaboration:

- Participation in IFCC (International Federation for Clinical Chemistry and Laboratory Medicine) group on quality in Clinical Laboratories
- International Working Group for the definition of the Platform for the recognition of Clinical Biology Exercise in E.U with the European Commission in Brussels
- EC<sub>4</sub> working group on Register for European Clinical Biologists
- IFCC/SFBC/FIP CBS/EC<sub>4</sub> working group on creation of a collaborative association for Clinical Biology and Laboratory Medicine in Europe. The main objective of this group is to develop collaboration between the 35 European countries issued from the UEO and to create a federative association (EFCC).

## Special Projects

We want to develop with FIP headquarters, BPP and YPG section a project for the next 2 years:

### Objectives:

- Increase visibility of the CBS;
- attract new members;
- work within a topic that is of interest to all within the profession.

### Potential Topics:

- Good practice of clinical biology
- Evidence of the impact of clinical biology in primary care
- Comparison of clinical biology practice in Europe

**Process:** Subject under discussion under CBS Bureau members. Involvement of BPP special projects, YPG and IPSF still under discussion.

### Next steps:

- Seek and find an intern/student to help the CBS on the project;
- Apply for special project financing from the BPP.

## Community Pharmacy Section (CPS)

38

### Overview

The Community Pharmacy Section is the largest of the FIP sections. With reference to the Steering Committee and the Board of Pharmaceutical Practice the responsibility of the activities of the Section lies with the Executive Committee.

The activities decided by the Executive Committee and the Steering Committee are implemented by the Section as well as by the "Foundation for Continuing Education Activities of the Section for Community Pharmacists of FIP", founded in 1987.

### Members

According to the FIP Secretariat, the number of members of the Community Pharmacy Section during the period represented in this Annual Report is 1888 members.

### Executive Committee

The new Executive Committee (ExCo) was elected during the Steering Committee meeting of the Section in Beijing. After the elections the ExCo consisted of following members:

Martine Chauvé, <i>France</i>	PRESIDENT
Dominique Jordan, <i>Switzerland</i>	VICE PRESIDENT
Eeva Teräsalmi, <i>Finland</i>	SECRETARY
Avi Moshenson, <i>Israel</i>	IMMEDIATE PAST PRESIDENT
Samira Goussous, <i>Jordan</i>	
Eugene Lutz, <i>USA</i>	
Warren Meek, <i>Canada</i>	
Hemant Patel, <i>UK</i>	
Ema Paulino, <i>Portugal</i>	
Patti Payne, <i>Australia</i>	

## Strategic Plan for Community Pharmacy Section

The new strategy plan and action plan for the Section were accepted by the ExCo in 2007.

The **mission** is to assist pharmacists, wherever they live and practice, in the delivery of medicines, health products and services that will improve medicine use and advance patient care.

The **vision** for the Community Pharmacy Section is:

- To develop strong relationships with all pharmaceutical associations that have focus on community pharmacists and pharmacists with other primary care functions and services
- To support pharmacists so that they can fulfil their responsibilities towards society and provide their services at a high professional level
- To be a "meeting point" for pharmacists so that CPS can facilitate further development of pharmacy practice within the primary health care sector in countries all over the world.

The strategy has three main areas of activities:

### Strategy 1: CPS as a resource centre

The overall goal is to be a proactive resource centre for national and international pharmaceutical associations for community pharmacists as well as for the overall FIP organisation.

### Strategy 2: Advancing community pharmacy practice

The overall goal is to assist members in managing change and ultimately to advance community pharmacy practice, by providing them with the necessary tools to effectively make the needed transitions in a changing environment.

### Strategy 3: Improving communication

The overall goal is to enhance communication to internal and external stakeholders ultimately supporting and recruiting members.

The Executive Committee will continue to devote attention to the strategic planning process in 2008 and will report on these issues at the meeting of the Steering Committee in September 2008.

## Congress Activities

### 67<sup>TH</sup> FIP CONGRESS BEIJING, CHINA, 2007, activities presented

ACTIVITY	TITLE	CHAIR, if applicable
Symposium and a visit programme, separate registration required	Introduction to Chinese Pharmacy practice	Eugene Lutz, USA, and Cai Weimin, China
Forum for Innovators in Pharmacy Practice (plenary lectures and workshops), separate registration required	Pharmacist advice at the counter - Implementation of Best Practice Standards	Hanne Herborg, Denmark, and Charlie Benrimoj, Australia
Symposium, joint with Industrial Pharmacy Section	Pharmaceuticals and the Environment	Astrid Kågedal, Sweden, and Erich Sturzenegger, Switzerland
Symposium, joint with Industrial Pharmacy Section	How to guarantee the Best Therapeutic Outcome of a Pharmaceutical Product - the Influence of a Life Cycle	Eeva Teräsalmi, Finland, and Tom Sam, The Netherlands
Forum for Policy Makers in Pharmacy Practice, joint witYPG and IPSF	Trends in Community Pharmacy - debating the Future of the Profession	Ema Paulino, Portugal, and Dick Tromp, The Netherlands
Steering Committee Meeting	The Chinese Pharmacists and their environment	Martine Chauvé, France
Business Meeting	Steering Committee Meeting	Martine Chauvé, France
Symposium	Customer Relationships	Prafull D. Sheth, India, and Hanne Herborg, Denmark
Practitioners' Day - Short Oral Presentations	Innovative Ways of Collaboration between Community Pharmacists and GPs	Patti Payne, Australia, and Dominique Jordan, Switzerland
Practitioners' Day - Short Oral Presentations	Management - a Challenge in Pharmacy Practice	Patti Payne, Australia, and Dominique Jordan, Switzerland
Practitioners' Day - Short Oral Presentations	Counterfeit Medicines	Samira Goussous, Jordan, and Eugene Lutz, USA
Practitioners' Day - Short Oral Presentations	The Role of the Pharmacist in Public Health	Samira Goussous, Jordan, and Eugene Lutz, USA
Poster Presentations	<ul style="list-style-type: none"> <li>• Innovative Ways of Collaboration between Community Pharmacists and GPs</li> <li>• Management - a Challenge in Pharmacy Practice</li> <li>• Counterfeit Medicines</li> <li>• The Role of the Pharmacist in Public Health</li> <li>• Other topics</li> </ul>	

Symposium, joint with Pharmacy Information Section and Hospital Pharmacy Section	The use of Informatics to improve Medication Safety From	Graeme Vernon, Australia, Ema Paulino, Portugal, and Marianne Ivey, USA
Continuing Education Programme, separate registration required	Research to Daily Practice: Implementing "Family Pharmacy" - an innovative Strategy and Business Model	Olivier Bugnon, Switzerland

## 68<sup>TH</sup> FIP CONGRESS BASEL, SWITZERLAND, 2008, activities planned

ACTIVITY	TITLE	CHAIR, if applicable
Forum for Innovators in Pharmacy Practice (plenary lectures and workshops), separate registration required	Change Management in Pharmacy Practice	Hanne Herborg, Denmark, and Charlie Benrimoj, Australia
Symposium, joint with Pharmacy Information Section, PGEU, and EuroPharm Forum	Global Perspectives of Pharmacy Changes in Europe	Martine Chauvé, France
Symposium, joint with Pharmacy Information Section	Can Technology Help to Reach Better Adherence to Medications?	Eva Sjökvist-Saers, Sweden, and Hanne Herborg, Denmark
ICT Showcase, joint with YPG and the following sections: Pharmacy Information, Military and Emergency, Hospital Pharmacy, and Industrial Pharmacy	IT-solutions in Pharmacy Practice, preview and highlights	Han de Gier, The Netherlands, Bill Felkey, USA, and Warren Meek, Canada
Forum for Policy Makers in Pharmacy Practice, joint with Industrial Pharmacy Section, YPG and IPSF	Trends in Community Pharmacy - debating the Future of the Profession	Dick Tromp, The Netherlands, and Ulf Janzon, Sweden
Symposium, joint with the following Sections: Clinical Biology and Laboratories and Medicines Control Services.	Cooperation between Clinical Biologists, Pharmacists and Physicians for the Benefit of the Patient	Bernard Poggi, France
Steering Committee Meeting	Community Pharmacy - Business or Healthcare? Perspectives from Different Countries	Martine Chauvé, France
Business Meeting	Steering Committee Meeting	Martine Chauvé, France
Symposium, joint with Pharmacy Information Section	Medicines Information for Patients	Theo Raynor, UK

Practitioners' Day - Short Oral Presentations and Discussions	The Role of the Pharmacist in Public Health	Astrid Kågedal, Sweden, and Warren Meek, Canada
Practitioners' Day - Short Oral Presentations and Discussions	Medication Review and other New Pharmacy Services	Katja Hakkarainen, Finland, and Hemant Patel, UK
Practitioners' Day - Short Oral Presentations and Discussions	Quality Assurance in Community Pharmacy	Eeva Teräsalmi, Finland, and Samira Goussous, Jordan
Practitioners' Day - Short Oral Presentations and Discussions	New Ways of Collaboration between Pharmacists and between Pharmacists and other Healthcare Professionals, including Managed Care, Collaborative Practice	Patti Payne, Australia, and Eugene Lutz, USA
Poster presentations	<ul style="list-style-type: none"> <li>• Medication Review and other New Pharmacy Services</li> <li>• The Role of the Pharmacist in Public Health</li> <li>• Quality Assurance in Community Pharmacy</li> <li>• New Ways of Collaboration between Pharmacists and between Pharmacists and other Healthcare Professionals, including Managed Care, Collaborative Practice</li> <li>• Other topics</li> </ul>	
Symposium, joint with Pharmacy Information Section	Pharmacoeconomics for Practitioners: an Opportunity to Enhance your Practice	Alan Lyles, USA, and Eeva Teräsalmi, Finland

## Communication

The Community Pharmacy Section has in the period from 1 April 2007 till 1 April 2008 issued 5 issues of ZOOM and 10 issues of Professional News. Both communications are electronic and go to all members of the Community Pharmacy Section, with Professional News reaching a broader range of people. Members are encouraged to forward these communications to interested partners.

## Internal/External Collaboration

- The Community Pharmacy Section has during the FIP congress in Beijing collaborated with Industrial Pharmacy Section, Pharmacy Information Section, Hospital Pharmacy Section, YPG and IPSF.
- The Section has collaborated with YPG in supporting their grants programme.

- The Community Pharmacy Section contributes to establishing a GPP-project in Jordan. This project was started in 2007 in Jordan with the establishment of a national committee. The Section provided the committee with suitable material and will send a lecturer to the GPP-symposium to Jordan on 11.4.2008. Ms Samira Goussous is the ExCo link to the Jordanian project.
- Collaboration with BPP - members in the working groups.

## Special Projects

Over the past year the Statutes of the Community Pharmacy Section have been revised. The new proposal for the Statutes was presented and adopted by the Steering Committee on 4 September 2007 in Beijing. The approved Statutes will be brought to a decision at the Council meeting in connection with the congress in Basel in 2008.

Report on "The role of the pharmacists in public health": A working group established by the Executive Committee (Christine Glover, UK, Astrid Kågedal, Sweden, and Eeva Teräsalmi, Finland) are the authors of the report which was presented to the Steering Committee in Beijing. The report consists of a theoretical portion and a section about presentations given during the Section programme during FIP Congresses in 2005, 2006 and 2007.

The Section has supported a project by Katja Hakkarainen, Finland: "Models of medication review - an international comparison". The results will be presented at the FIP Congress 2008 in Basel.

The Section has decided to establish a task force for a new project: "Quality work in pharmacies - how to develop indicators for change processes and outcomes". The main goals for the project are to follow and research implementation strategies at the pharmacy level and develop suitable ways of measuring the outcomes of pharmacist actions.

## Hospital Pharmacy Section (HPS)

### Overview

The overall goal of the Hospital Pharmacy Section (HPS) remains to advance the opportunities for pharmacists practicing in hospitals and organised health care settings to improve patient care by optimising the use of medications. The dominant feature of the past year has been the planning for the Global Conference on the Future of Hospital Pharmacy, to be held in Basel, Switzerland from 30-31 August 2008. The Section has continued to place emphasis on improved communication between its members, contribution to wider FIP activities (though, for example, contributions to the work of various Working Groups and inputs to documents and policies that are of relevance to practice in this arena). Considerable use has been made both of the FIP web site of the newly provided 'listserv' capacity. On an organisational level, the duties of the HPS Vice-Presidents have been outlined in detail, and each has been allocated a defined list of countries with which to liaise, aligned as far as possible with the World Health Organization (WHO) regions. The current Vice-Presidents are able to cover the WHO AFRO,

WPRO, SEARO, EURO and AMRO (PAHO) regions, but not EMRO. The HPS Council intends to co-opt someone to represent this region and then to consider an amendment to the constitution of the Council. However, the challenges of truly engaging with this many countries cannot be under-emphasised. One of the targets of this action will be to encourage individual membership of the Section.

### Number of Members (as of 1 March 2008)

As per the last membership distributed, HPS had 440 paid-up members.

### Executive Committee (as of 1 March 2008)

Andy Gray, <i>South Africa</i> E-mail: graya1@ukzn.ac.za	PRESIDENT (2006-2010)
Stephen J Curtis, <i>United Kingdom</i> , E-mail: stephenfip@aol.com	SECRETARY (FIRST TERM, 2004-2008)
Lee Vermeulen, <i>USA</i> E-Mail : lc.vermeulen@hosp.wisc.edu	ASSISTANT SECRETARY (FIRST TERM, 2004-2008)
Toby Clark, <i>USA</i> E-mail: tobyclark@att.net	TREASURER (FIRST TERM, 2006-2010)
Roger L Tredree, <i>UK</i> E-mail: rltredreefip@tiscali.co.uk	IMMEDIATE PAST PRESIDENT (2006-2010)
Rebecca Buckle Nordorl, <i>Ghana</i> E-mail: kaibuckle@yahoo.com	VICE PRESIDENT FOR AFRICA (FIRST TERM, 2006-2010)
Rebekah Moles, <i>Australia</i> E-Mail: rebekahm@pharm.usyd.edu.au	VICE PRESIDENT FOR AUSTRALASIA (FIRST TERM, 2004-2008)
Jacqueline Surugue, <i>France</i> E-mail: jsurugue@gmail.com	VICE PRESIDENT FOR EUROPE (FIRST TERM, 2006-2010)
Katsushi Yamada, <i>Japan</i> E-mail: yamada@m3.kufm.kagoshima-u.ac.jp	VICE PRESIDENT FOR JAPAN (SECOND TERM, 2006-2010)
Marianne F Ivey, <i>USA</i> E-mail: iveymf@healthhall.com	VICE PRESIDENT FOR NORTH AMERICA (FIRST TERM, 2006-2010)

### Strategic Plan

The overall mission of the section is to further hospital pharmacy in all its aspects. Put in simple terms it can be encapsulated as "defining, promoting and realizing an envisioned future".

In order to achieve this, the following specific objectives have been elucidated:

- to promote the exchange of views on professional subjects relating to the duties and responsibilities of hospital pharmacists;
- to promote pharmaceutical care for patients in hospital related facilities;

- to foster continuous education programs for hospital pharmacists;
- to promote the realisation of the goals of FIP as they apply to hospital pharmacists;
- to pay particular attention to the needs of developing countries; and
- to promote integrating pharmacy services through communication and collaboration with other sections.

The HPS is also committed to achieving the broad strategic aims of the Board of Pharmacy Practice. In redefining the envisioned future by means of the Global Conference 2008 and the Global Hospital Pharmacy Survey, it is mindful of the need to partner with patients, enhance pharmacy practice, develop better financial models, promote evidence-based practices, assure competency and the provision of a sufficient workforce.

## Congress Activities

### 67<sup>TH</sup> FIP CONGRESS BEIJING, CHINA, 2007, activities presented

ACTIVITY	TITLE	CHAIR, if applicable
Accredited conference sessions	• Clinical Trials in Asia	• Toby Clark (co-hosted with the Industrial Pharmacy Section)
	• The use of informatics to improve medication safety	• Marianne Ivey (co-hosted with the Pharmacy Information and Community Pharmacy Sections)
	• Responding to global and local emergencies	• Rebekah Moles (co-hosted with the Military and Emergency Pharmacy Section)
Poster sessions	<ul style="list-style-type: none"> <li>• 100 posters were accepted for display</li> <li>• An award for the best poster was made, with honourable mention for 2 others</li> </ul>	• Rebekah Moles
Hospital visits	• Visits to 2 local hospitals	• Andy Gray, Stephen Curtis
FIP booth		• All HPS Council members
FIP Showcase		• All HPS Council members

### 68<sup>TH</sup> FIP CONGRESS BASEL, SWITZERLAND, 2008, activities planned

ACTIVITY	TITLE	CHAIR, if applicable
Pre-conference symposium Accredited conference sessions	• Global Conference on the Future of Hospital Pharmacy	• Lee Vermeulen, Arnold Vulto
	• Making Paediatric Medicines work	• Andy Gray (to be co-hosted with the Industrial Pharmacy Section)

ACTIVITY	TITLE	CHAIR, if applicable
Pre-conference symposium Accredited conference sessions	<ul style="list-style-type: none"> <li>Clinical Pharmacy Practice in the Hospital Setting - From Dreams to Reality</li> </ul>	<ul style="list-style-type: none"> <li>Marianne Ivey (to be co-hosted with the International Pharmacy Students Federation)</li> </ul>
	<ul style="list-style-type: none"> <li>Applying the Consensus Statements of the Global Conference on the Future of Hospital Pharmacy.</li> </ul>	<ul style="list-style-type: none"> <li>Stephen Curtis and Lee Vermeulen</li> </ul>
Poster sessions	<ul style="list-style-type: none"> <li>Call for abstracts issued</li> </ul>	<ul style="list-style-type: none"> <li>Stephen Curtis</li> </ul>
Hospital visits	<ul style="list-style-type: none"> <li>In planning</li> </ul>	<ul style="list-style-type: none"> <li>Stephen Curtis</li> </ul>
FIP booth		<ul style="list-style-type: none"> <li>All HPS Council members</li> </ul>
FIP Showcase		<ul style="list-style-type: none"> <li>All HPS Council members</li> </ul>

## Communication

Three main communication channels are employed - the HPS electronic newsletter, the FIP-HPS listserv and the FIP web site.

As planned, six issues of the e-Newsletter were distributed (on 14 March 2007, 11 June 2007, 27 August 2007, 12 October 2007, 29 December 2007 and 22 February 2008). In addition to carrying news of previous Congresses, and details of the planned Global Conference, the e-Newsletter has carried profiles of the HPS Council members and either abstracts or extended versions of poster presentations made at previous Congresses. Another newsletter will be issued in early April 2008 focusing on the call for abstracts for the Basel poster session.

46

After a rocky start, the FIP-HPS listserv has settled, and is being used to distribute the electronic newsletter and also to carry other messages from HPS Council members, FIP staff and to provide a forum for engagement with members.

The website has been updated and now carries the following active sections:

- contact details of officers;
- the broad strategic focus of the Section;
- the section contact email address ([hps@fip.org](mailto:hps@fip.org));
- back issues of the 2006, 2007 and 2008 electronic newsletters;
- a detailed section on the Global Conference (accessible directly at [www.fip.org/globalhosp](http://www.fip.org/globalhosp)).

Updated materials were prepared, displayed and distributed at the Beijing Congress. These included the Section Poster displayed at the Showcase, as well as copies of the e-Newsletter and brochure made available to congress attendees at that event and via the FIP booth. HPS Council members were on hand to engage with prospective members. In addition, the Global Conference was marketed at the Basel stand. Press releases announcing the Global Conference and the major sponsorship have also been issued.

## Internal/External Collaboration

A key element of internal collaboration has been the preparation and presentation of joint accredited sessions at the FIP Congresses. In 2007, the HPS collaborated with the Industrial Pharmacy Section,

Pharmacy Information Section, Community Pharmacy Section and the Military and Emergency Pharmacy Section in this way. Accredited sessions have been planned for the 2008 Congress with the Industrial Pharmacy Section and the International Pharmacy Students Federation). Rebekah Moles (HPS Vice President for Australasia) continues to be engaged with the "Medicines Information to Children and their Carers", an ongoing project supported by the FIP Young Pharmacists Group Innovation Award.

Internally, the HPS has contributed to various working groups:

- the final report of the BPP Working Group on Patient Safety;
- the BPP Working Group on Collaborative Practice (Jill Martin, Andy Gray); and
- the BPP Working Group on Good Pharmacy Practice (Jacqueline Surugue).

Externally, input was provided on the proposed revision of the Declaration of Helsinki by the World Medical Association, the draft WHO/FIP "Developing Pharmacy Practice - a Focus on Patient Care" manual. Contact has been maintained with the Joint Commission International, which had issued revised Accreditation Standards for Hospitals in 2007 (to which the Section provided input).

In the planning for the Global Conference, close contact has been developed and maintained with a number of national and regional hospital pharmacy associations, including the European Association of Hospital Pharmacists and the American Society of Health-System Pharmacists. The congresses of both organisations have been used to promote the Global Conference.

## Special Projects

In 2007, the BPP funded a Special Project entitled "A Survey of Global Hospital Pharmacy Practice", to be conducted by the Hospital Pharmacy Section, with the following aims:

- to identify key issues facing international pharmacy practice, thus providing information which would be useful for strategic planning, goal-setting and in directing future programming for the FIP Hospital Pharmacy Section;
- to create comparative benchmarking information which could aid national hospital pharmacy organizations to set goals and agendas for the future, by assessing the feasibility of advancing pharmacy practice in every country;
- to provide fundamental underpinning information for the 2008 Global Conference on the Future of Hospital Pharmacy.

The final survey instrument (in English, French and Spanish) was fielded to contacts in 90 of the 192 United Nations-recognized countries. At time of writing, responses had been received from 63 countries (77.4% of the world's population). If responses were received from those additional countries which had identified respondents, coverage of 85.1% of the world's population would be achieved. However, countries with medium and low Human Development Index scores, notably from the WHO EMRO, WPRO and AFRO regions, would remain under-represented. An interim analysis is planned for March 2008, to provide data to for the Global Conference facilitators. Closure of the survey and locking of the database is planned for 1 May 2008. Final analysis results will be provided by June 2008. The results of the survey will be presented at the Global Conference in August 2008 and widely published thereafter.

# Industrial Pharmacy Section (IPS)

## Overview

Founded in 1955, FIP's Industrial Pharmacy Section (IPS) has expanded to a worldwide industrial pharmacy network with many regular activities. IPS strives to spread its activities across the different regions, involving both participants and organisations from developing and developed countries, focusing on young pharmacists and students.

Currently, the Section's emphasis lies on the quality of medicines, but other topics such as clinical trials, pharmacy education, orphan drugs are also explored. To this end IPS broadly co-operates with other sections in the BPP; with special interest groups in the BPS; and with outside parties including national and (supra-) regional industry associations, scientific and professional societies (ISPE, BODL, AAPS, EUFEPS, etc), and health regulatory agencies and inspectorates (EMA, FDA).

IPS is active in several working groups, such as the PharmaBridge Project, the FIP Patient Safety Working Group, the IPS Expert Group for WHO Document Review, the IPS Working Group on the Definition of Quality and the IPS Tableting and Tooling Working Group.

## Members

The number of members of the Industrial Pharmacy Section during the period represented in this Annual Report is 459 members.

48

## Executive Committee

Dr Tom Sam, <i>The Netherlands</i>	PRESIDENT
Henriette Jansen, <i>The Netherlands</i>	GENERAL SECRETARY
Dr Rajni Jani, <i>USA</i>	TREASURER
Dr Linda Hakes, <i>USA</i>	VICE PRESIDENT
Dr Erich Sturzenegger, <i>Switzerland</i>	COORDINATOR OF SOCIAL PROGRAM
Pof. Adel Sakr, <i>USA</i>	CONGRESS CHAIR
Dr Claudia Rijcken, <i>Switzerland</i>	PUBLICATION OFFICER
Avanathi Govender, <i>South Africa</i>	PSF/YPG LIAISON
Ulf Janson, <i>Sweden</i>	WORKING GROUP LIAISON OFFICER

## Affiliated ExCo Members

Michael H. Anisfeld, <i>USA</i>	WORKING GROUP WHO
Dr Mathew Cherian, <i>Italy</i>	MEMBERSHIP MANAGER
Rik Eijgelshoven, <i>Switzerland</i>	IPS NEWSLETTER EDITOR
Erik Naeser, <i>Sweden</i>	

## Strategic Plan

A detailed strategy for IPS for the coming years will be discussed at the IPS ExCo meeting, end March 2008. Preliminary evaluation of input received from our Executive and our Advisory Committee indicates that IPS is not considering itself to be adequately fulfilling the requirements of its current mission statement: to present and serve the pharmaceutical profession and pharmaceutical sciences within the pharmaceutical industry worldwide. IPS is playing a modest role within FIP, despite its role in joint activities including the WHO/FIP Meetings on pediatric dosage forms, the FIP/RPSGB Quality-International meetings, the FIP/AAPS Workshops on Quality and the workshops organized under the BPP PharmaBridge flag. Also outside FIP the influence of IPS cannot be considered extensive, despite cooperation with organisations such as EMEA, EUFEPS and EFPIA.

Realising that long term dedication is needed, IPS will pursue the above activities, but will pay more attention to areas outside the traditional quality arena, including clinical, toxicology, environmental and marketing. IPS will continue to support and invest in meetings in developing countries and stimulate the activities of the next generations of industrial pharmacists.

## Congress activities

### 67<sup>TH</sup> FIP CONGRESS BEIJING, CHINA, 2007, activities presented

ACTIVITY	TITLE	CHAIR, if applicable
Workshops on Pharmaceutical Manufacturing Science and Practice: 4 parallel workshops prior to FIP Congress Beijing	Good Manufacturing Practices for the 21st Century	Prof. M.H. Anisfeld
	Quality by Design and Quality Risk Management	Dr A.P. Sam
	Tableting, PAT and Controlled Release Technologies	Prof. Dr. A.S. Sakr
	Parenteral Technology, Validation and Quality Assurance	Dr M. Cherian
Session	Pharmaceuticals and the Environment	Dr E. Sturzenegger
Session	How to guarantee the best therapeutic outcome of a pharmaceutical product - the influence of a life cycle	Dr L.B. Hakes
Session	Clinical Trials in Asia	Dr C.A.W. Rijcken
Session	Good Manufacturing Practice (GMP) & Good Clinical Practice (GCP)	Dr A.P. Sam
Session	Nanotechnology - From Science to Industrial Practice	Dr A.P. Sam
Oral Presentations	Short Oral Presentations (part I): Manufacturing and Good Manufacturing Practice	Prof. Dr. A.S. Sakr

IPS Business Meeting	Progress in Industrial Pharmacy and Drug Development	Dr. A.P. Sam
Oral Presentations	Short Oral Presentations (part II): Drug Delivery	Prof. Dr. A.S. Sakr

## 68<sup>TH</sup> FIP CONGRESS BASEL, SWITZERLAND, 2008, activities planned

ACTIVITY	TITLE	CHAIR, if applicable
Workshops on Pharmaceutical Science and Practice: 6 parallel workshops prior to FIP Congress Basel	Meeting the Challenges on Pharmaceutical Innovation and Quality by Design in the 21st Century: Implementation of PAT	Prof. Dr. A.S. Sakr Dr A. Hussain Dr M. Khan
	Advances in Biotechnology	Dr M. Cherian and Dr. H. Levin
	Current Concepts in Good Manufacturing Practices (GMP)	Prof. M.H. Anisfeld Dr L.B. Hakes
	Theory and Practice of Aseptic Processing using Isolator Technology (Emphasizing Applications for Biotech Products)	Dr P. Ruffieux Dr M. Yelviggi
	Novel E-tools for Robust Solid Dosage Form Design	Prof. Dr. H. Leuenberger Mr E. Naeser
	Modern Solid Dosage Form Process Design and Development	Dr A.P. Sam Dr G. Bretz
Showcase	ICT Showcase	Mr U. Janzon (IPS representative)
Oral Presentations	Short Oral Communications on Pharmaceutical Manufacturing and Drug Delivery Technologies	Prof. Dr. A.S. Sakr
Session	Meeting the Pharmacy Education Needs for a Career in Pharmaceutical Industry or Research	Dr L.B. Hakes
Session	Implementation of Quality by Design and Risk Management - Overcoming the Practical Hurdles	Dr A.P. Sam
Session	Advances in Clinical Trials	Dr C.A.W. Rijcken

## Communication

Four IPS Newsletters were published in 2007.

### Volume 4 Issue 1 - July

- Presenting the coming FIP congress in Beijing
- Highlights from the FIP congress in Salvador

#### Volume 4 Issue 2 - September

- Presenting the complete IPS schedule for the Beijing congress
- Report from the Forum Pharmaceutique International African, Lomé, Togo
- Presenting the IPS Medal of Excellence award winner Professor Abdel Aziz Saleh

#### Volume 4 Issue 3 - October

- Report from the Asia Pacific Pharmaceutical Symposium held in Katmandu, Nepal
- Looking back on the highlights from the past FIP congress in Beijing

#### Volume 4 Issue 4 - December

- Invitation to Basel together with a detailed description of the several activities surrounding this coming FIP congress
- Presenting the student award winners from the FIP congress in Beijing

### Internal Collaboration

- BPS - Congress Session
- FIP - see external collaboration
- HPS - Congress Session
- IPSF - Mike How Award
- YPG - Mike How Award

### External Collaboration

- AAPS
  - CPA
  - EUFEPS
  - IPA
  - NIA
  - NVFW
  - RPSGB
  - WHO
- 
- **FIP/AAPS/IPA Workshop on Quality**, GMPs for the 21st Century, Mumbai, India, February 2008
  - **FIP Quality-International 2007 Conference**, Critical Process Parameters in the Manufacture of APIs, Biologicals, Tablets and Parenterals, London, UK, November 2007. Organized together with the Royal Pharmaceutical Society of Great Britain.

### IPS Sponsored Events:

- FIP/NIA/NVFW session, Regulatory Science, the Netherlands, October 2007
- Asia Pacific Pharmaceutical Symposium, Kathmandu, Nepal, June 2007
- 8<sup>ème</sup> Forum Pharmaceutique International, Lomé, Togo, June 2007
- China International Pharmaceutical Technologies Conference, Shanghai, May 2007
- Training Course on Quality Management in Pharma and Biotech (4 modules), the Netherlands

## Special Projects

### IPS Medal Award

The IPS Medal Award aims to recognize an individual who has given an outstanding contribution to pharmaceutical science and practice within industry and related fields. These contributions can be made in the several work fields of industrial pharmacists: production, quality control and assurance, research and development, marketing and general management. The award presents a medal and is submitted annually on the occasion of the FIP congress.

The IPS medal 2007 was awarded to Prof. Saleh, WHO.

### Mike How Award

The Mike How Award aims to support pharmacy students and young pharmacists, preferably from developing countries, to attend one FIP congress. The award is granted annually to a pharmacy student or young pharmacist who has shown a keen interest and passion for the Industrial Pharmacy sector. They may be involved in, or conducting Industrial Pharmacy research, or actively working in the Industrial Pharmacy environment. The recipient will benefit from the attendance to the FIP congress and Industrial Pharmacy Workshops by expanding his/her knowledge and obtaining exposure that he/she can use to enhance and influence their Industrial Pharmacy career. For this purpose, the definition of Industrial pharmacy includes the development, manufacturing and regulatory aspects of Pharmaceuticals. The award consists of an amount of up to 1000 euros to be used in support of transport, accommodation and registration for the annual FIP congress as well as free attendance to the IPS pre-satellite workshops.

The Mike How award 2007 was awarded to Mr Uttam Budhathioki, Nepal.

52

## Laboratories and Medicines Control Services Section (LMCSS)

### Overview

The Laboratory and Medicinal Control Section (LMCS) was officially formed in 1980 at the Madrid FIP Congress following having been a committee for more than 60 years. The mission of the section is the research and development of methods used to establish principles for assuring the quality of pharmaceutical and medical products both nationally and internationally and to exchange information and opinions upon technical and professional issues pertaining to medicines control and quality assurance.

### Number of Members

LMCS has 75 paying members and working relationships with 50 laboratories.

## Executive Committee

Frans van de Vaart, <i>The Netherlands</i>	PRESIDENT
António Bica, <i>Portugal</i>	SECRETARY
Henning Blume, <i>Germany</i>	
Johannes Krämer, <i>Germany</i>	
Tony Moffat, <i>UK</i>	
Segei Sur, <i>Ukraine</i>	

## Strategic Plan

In order to achieve its mission the section currently undertakes several activities:

### 1. Improve quality standards of medicines control laboratories by supporting the development and accreditation of quality systems via the organisation of proficiency testing

In 2007, the 9th round of the LMCS proficiency testing program (PTP) was held. Forty-seven labs from 41 countries analysed 2 samples: a buffer solution for pH measurement and a potassium chloride oral solution for the assay of potassium. Results were evaluated and reported to the participants. Colleagues from eight labs participating in this process also applied as new members of LMCS.

The 10<sup>th</sup> round is currently running; samples have been distributed and results are expected in the next month.

### 2. Initiate collaborative studies on the quality of medicines

LMCS currently runs a study on suspected counterfeit medicines. Fifty batches of antibiotics, anti-malarial and antiretroviral medicines were collected in North African countries; results are currently pending.

### 3. Act as an information centre in the field of quality of medicines

The section president participated on behalf of FIP in the meeting of the Expert Committee on Specifications for Pharmaceutical Preparations, 15-19 October in Geneva.

### 4. Increase membership

In 2008 cooperation with other sections will be sought to draw attention to the benefits of being a member of LMCS for people working in the field of quality control of medicines. Also, official and unofficial labs in developing countries will be invited to become members and to participate in the PTP studies.

## Congress Activities

### 68<sup>TH</sup> FIP CONGRESS BASEL, SWITZERLAND, 2008, activities planned

ACTIVITY	TITLE	CHAIR, if applicable
Joint symposium with BPS	Biosimilars: from Science to Practice II	Tony Moffat, UK
Poster Session		

## Communication

The section published one newsletter.

## Internal/External Collaboration

LMCS worked with the BPS and SIG Biotechnology to organise a joint symposium Biosimilars: from Science to Practice II for the upcoming Congress in Basel. The Section also worked with the FIP Working Group on counterfeit medicines and with official labs in North African countries to collect samples for the anti counterfeit collaborative study.

Work also continues with about 50 laboratories in all parts of the world in the the LMCS PTP program.

# Military and Emergency Pharmacy Section (MEPS)

## Overview

The aim of the Section is to establish close co-operation between military pharmaceutical services and other organisations that provide pharmaceutical services in a humanitarian aid or emergency relief situation. The members have as their mission the study of problems relating to the provision of these services on an international basis and to co-ordinate pharmaceutical questions in general. Military health services often work together with International Relief Organisations in humanitarian aid situations. The logistics management of many of these non governmental organisations is manned by pharmacists, which in MEPS are given the description of emergency pharmacists.

54

## Number of Members

As at 28 Feb 08 MEPS had 66 active members. This is a small section because of the inherent difficulty in working with military organisations. Specifically these are:

- Not all countries have military pharmacists;
- Many countries cannot fund participation e.g. most African, some East and South European countries;
- Countries represented at the Congresses limit their delegation mostly to senior personnel; and
- The location of the Congress can influence participation based on political or military differences.

## Executive Committee

LCol R. Vaillancourt , *Canada*

PRESIDENT

Mrs J. Dawson, *New Zealand*

SECRETARY

Col H. Hoehn, *Germany*

VICE PRESIDENT

Maj R. Wosolobe, *Austria*

TREASURER

Maj I. Awle, *Kenya*

VICE PRESIDENT

## Strategic Plan

The members of MEPS have a very specific niche in pharmacy that encompasses many of the roles detailed in other sections. What are different for the MEPS pharmacist are the difficulties associated with working with the multiplicity of roles undertaken by a single individual in such diverse areas as in emergency situations, humanitarian aid situations, logistics as well as routine provision of healthcare, and patient education and communication. The MEPS strategic plan attempts to address some of the issues that arise in emergency practice.

Raise Professional Standards	<ul style="list-style-type: none"> <li>The scientific upgrading of the Newsletter by editing interesting scientific work within the niche of M&amp;E pharmacists' activities</li> <li>Undertaking special projects</li> </ul>	Ongoing
Develop Policy Related to Safe Use of Medications	<ul style="list-style-type: none"> <li>Participation in consultation between FIP and WHO on professional guidelines and standards</li> <li>Pictogram Project to increase patient understanding of medication use</li> </ul>	Ongoing
Expand Influence and Role of the Pharmacist	<ul style="list-style-type: none"> <li>The two Special Projects are developing tools that have multidisciplinary application and raise the profile of the pharmacist.</li> </ul>	Ongoing
Develop - Expand continuing education	<ul style="list-style-type: none"> <li>New medical material is showed and explained, sometimes by commercial companies, when it is in the professional interest of the members</li> <li>All presentations and interesting sent in articles are introduced into the MEPS Newsletters</li> </ul>	Ongoing
Encourage research	<ul style="list-style-type: none"> <li>The Special Projects encourage participation by all MEPS members</li> <li>New tools to encourage patient understanding of medication regimes are being developed</li> </ul>	Ongoing
Increase membership	<ul style="list-style-type: none"> <li>Collaboration with Pharmaciens sans Frontières (PsF)</li> <li>Liaising with Red Cross (Japanese branch)</li> <li>Attempting to increase membership through military liaisons</li> </ul>	

## Congress Activities

### 67<sup>TH</sup> FIP CONGRESS BEIJING, CHINA, 2007, activities presented

ACTIVITY	TITLE	CHAIR, if applicable
MEPS Meet and Greet		
Joint session with Pharmacy Information Section	Risk Communication In Patient Safety: to what extend pictograms can help in labelling?	LCol S. Groves
MEPS Board Meeting		
Day Visit with the Chinese People's Liberation Army	Hospital of the 3rd Guard Division 302 Hospital PLA	LCol Chen Z

MEPS Dinner		
MEPS Session	Responding to global and local emergencies	Col H. Hoehn Maj I. Awle
MEPS General Meeting		
Joint Session with Hospital Pharmacy Section	Responding to global and local emergencies	Mrs J. Dawson

## 68<sup>TH</sup> FIP CONGRESS BASEL, SWITZERLAND, 2008, activities planned

ACTIVITY	TITLE	CHAIR, if applicable
MEPS Meet and Greet		
Host sponsored educational visit: Field Hospital, Swiss Forces		
MEPS Board Meeting		
MEPS Dinner		
Full day session of presentations	Healthcare to Logistics, Pharmacy Practice in the Emergency Arena.	Col H. Hoehn Maj R. Wosolsobe
MEPS General Meeting (with elections)		

56

## Communication

### a. Newsletters:

Number 35	17 Feb 2007
Number 36	04 Mar 2007
Number 37	11 Apr 2007
Number 38	19 Jul 2007
Number 39	17 Nov 2007
Number 40	26 Feb 2008

### b. General Communications via email: 8

### c. Submissions to BPP: 6

### d. Updates to the website: newsletters and project updates

## Internal/External Collaboration

### a. Internal:

- Hospital Pharmacy Section; Joint session at Beijing
- Pharmacy Information Section; Joint session at Beijing

### b. External:

- Primary Health Care and Public Health, First Nations and Inuit Health Branch Health Canada. Work with Pictogram Special Project
- Pharmacists Without Borders, Canada. Work with Pictogram Special Project
- Hospital del Niño DIF in Pachuca, Mexico. Collaboration on Asthma Special Project
- Children's Hospital of Eastern Ontario, Canada. Collaboration with Pictogram and Asthma Special Projects

## Special Projects

### 1. Pictogram Project

The aims of this project are to:

- Design, validate, and evaluate pictograms to label medications.
- Identify culture-specific pictograms preferred based on continent of residence.

This project is in its fourth year and has many components to it. The progress this year has included: Conduction of an online survey through FIP in both English and Spanish; planning field testing in Haiti and Mali of low-technology stamps for field use of pictograms; further development of the electronic pictographic label program; and, generation and testing of new pictograms with the Canadian First Nation peoples. Developing culture-specific pictograms for increased comprehension has generated positive feedback from all communities and there is recognized value in having such a programme implemented into their framework. The online survey using a force choice method has identified appropriate modifications to medication pictographic instructions to reduce interpretation errors based on continent of cultural origin. The online pictogram program will be updated to reflect the information gathered from the survey.

### 2. Asthma Project

The aims of this project are to:

- Establish an international network of direct patient care pharmacists in order to develop and evaluate an evidence-based asthma patient counselling tool.
- Develop an evidence-based asthma action plan using pictograms as a supplementary aid to improve communication to both children and parents.
- Validate asthma action plan pictograms in children including different cultures.

At this time, 45 patients have been recruited and drawings collected for future analysis. The Hospital del Niño DIF in Pachuca, Mexico has obtained ethical approval to collect drawings from their chronic asthmatic paediatric patients and will commence recruiting patients this month. Information gathered from this study will support the multidisciplinary research team in decisions regarding the creation of asthma pictographic tools, improving the child's health literacy and allow children to be recognized as participants in their own medication use. In addition, results may lead to discovering whether multi-ethnic children process medical information and perceive asthma differently than their same-age colleagues. By better understanding how children perceive their condition, health care providers will be able to design pictographic instructions to better communicate health issues and long-term management to paediatric patients and their parents / guardians.

## Pharmacy Information Section (PIS)

### Overview

Throughout the past time period it was the underlying goal of the FIP Pharmacy Information Section (PIS) to uphold the overall mission and key activities of the Section, namely:

- provide a forum in which FIP members and other interested parties can expand and share their knowledge about information issues relating to pharmacy, medicines, and public health;
- promote networking between various groups that provide information services; and
- proactively reach out to enhance the public health and the work of the profession of pharmacy through medicine information programs and related activities and initiatives.

58

Promotional tools, material, meetings, other activities related to section/ FIP membership promotion include:

- Poster and brochures for Showcase at FIP Congresses
- ExCo members attended reception for newcomers at FIP Congress
- Members-only website hosted by FIP
- Geographic balance in promoting FIP and the Section is being ensured by electing Executive Committee members to represent specific regions (Europe, Africa/Middle East, Asia/Pacific, and the Americas).
- Membership promotion at the reception for newcomers at FIP Congress and by appeal in Section Newsletter to members to act as recruiters

### Working Groups

The various Working Groups are the "Back Bone" of the Section and have been established to cover the following topics:

- Access to Drug Information (chair: David Woods)
- Access to Medicines (co-chairs: Kevin Moody and Keith Johnson)
- Antimicrobial Resistance (chair: Daniel Seyoum)
- Complementary and Alternative Medicines (chair: Lana Dvorkin)
- Consumer Medicines Information - Improving Access for People with Special Needs (chair: Theo Raynor)

- Geriatrics Information (chair: William Simonson)
- Medicinal Drugs and Driving (chair: Han de Gier)
- Patient Counselling (chair: Marja Airaksinen)
- Performance-Based Design of Medicine Labelling (chair: Stein Lyftingsmo)
- Pharmabridge (has become BPP WG, chair: Agathe Wehrli)

## Members

The section is one of the fastest growing sections within the Board of Pharmacy Practice, with membership increased from 137 in 2002 to 310 (from close to 80 countries) to the end of February 2008.

## Executive Committee

Han de Gier, <i>The Netherlands</i>	PRESIDENT
Agathe Wehrli, <i>Switzerland</i>	SECRETARY
Kevin Moody, <i>The Netherlands</i>	TREASURER
Keith Johnson, <i>USA</i>	PAST-PRESIDENT
Alexander Doodoo, <i>Ghana</i>	
Carlos Vidotti, <i>Brazil</i>	
Graeme Vernon, <i>Australia</i>	
Marja Airaksinen, <i>Finland</i>	
Eiichi Akaho, <i>Japan</i>	
Francoise Pradel, <i>USA</i>	

## Congress Activities

### 67<sup>TH</sup> FIP CONGRESS BEIJING, CHINA, 2007, activities presented

ACTIVITY	TITLE	CHAIR, if applicable
Sessions	Two Days Pre-satellite Workshop: Strategies in Medication Safety - Pharmacovigilance and Preventing Medication Errors	
	Antimicrobial Drug Resistance - the Role of the Pharmacy Profession in tackling this emerging global health problem	
	Risk Communication in Patient Safety: to what extent can Pictogrammes help in Labelling? ( <i>with Military and Emergency Pharmacy Section</i> )	
	Evidence based Practice and Complementary Medicines: Teaching and Learning by Example ( <i>with FIP Academic Pharmacy Section</i> )	
	Medication Reviews - from Medication Counselling towards Service Delivery ( <i>with IPSF</i> )	

ACTIVITY	TITLE	CHAIR, if applicable
Sessions	Good versus bad Drug Information in the Public Domain - can you spot the Difference? <i>(with YPG)</i>	
	The Use of Informatics to improve Medication Safety <i>(with FIP Community Pharmacy Section and Community Pharmacy Section)</i>	
	Current Issues on Drug and Healthcare Information	
Poster Presentation		

## 68<sup>TH</sup> FIP CONGRESS BASEL, SWITZERLAND, 2008, activities planned

ACTIVITY	TITLE	CHAIR, if applicable
Pre-satellite Symposium:	FIP Community Pharmacy Section	
Global Perspectives of Pharmacy Changes in Europe	This programme will be organised in collaboration with the FIP Pharmacy Information Section, the Pharmaceutical Group of the European Union and EuroPharm Forum.	
Sessions	Medicines information for patients	
	Can technology help to reach better adherence to medications?	
	Current issues on drug and healthcare information	
	Pharmacoeconomics for practitioners: an opportunity to enhance your practice, part I and II	
	Medication reviews - collaboration between pharmacists, physicians and patients (joint with international pharmaceutical students' federation)	
	Patients in control of their records	
	ICT Showcase: Preview and Highlights FIP Pharmacy Information Section FIP Hospital Pharmacy Section FIP Young Pharmacists Group FIP Community Pharmacy Section FIP Military and Emergency Pharmacy Section FIP Industrial Pharmacy Section	

### Communication

The Section has been active in networking with its membership through:

- Info-Link Newsletter four issues
- Members-only website hosted by FIP
- Business meeting minutes e-mailed to section members

## Internal/External Collaboration

Different Executive Committee members and Chairs of the Section's Working Groups have been active in participating in various FIP, BPP and WHO projects:

- Running of Pharmabridge project by Section's Secretary who chairs the BPP Sub-Committee on Pharmabridge.
- Participating in BPP Programme Committee (Section's President)
- Participating in BPP Committee on Section Incentive Award Strategy Evaluation (Section's President)
- Participation in BPP ExCo (Section's President)
- WHO drafts are regularly forwarded to ExCo and WG coordinator

## Special Projects

*Stipend programme for pharmacists and students from developing and transitional countries*

Four young pharmacists were attending the Beijing Congress thank to PI Section stipends: Inese Svestina from Latvia, and Dhaka Ram Bhandari, Nilima Shresta, Ganesh Prasad Subedi, all three from Nepal.

*Results of WG activities:*

- A curriculum for training people to work in Drug Information Centres is under development.
- FIP Policy statements emanating from PI working groups to be presented in Basel on:
  - Medicines information for patients
  - Antimicrobial resistance





# Regional Pharmaceutical Forums

Regional pharmaceutical forums bring together national pharmacy associations, the World Health Organization (WHO) and FIP in six regional platforms. The aim of the Forums is to increase partnership, dialogue, understanding and activity in different world regions, enabling the pharmacy profession to have a greater impact on improving pharmacy services and health by focusing on distinct local needs.

The Regional Pharmaceutical Forums have been formed in WHO's six geographical subdivisions

- **Europe:** EuroPharm Forum (est 1992); [www.euro.who.int/europharm](http://www.euro.who.int/europharm)
- **America:** Pharmaceutical Forum of the Americas (est 2000); [www.paho.org/English/HSP/HSE/ffa-eng.htm](http://www.paho.org/English/HSP/HSE/ffa-eng.htm)
- **South-East Asia:** SEARPharm Forum (est 2001); [www.searpharmforum.org/EN/Index.htm](http://www.searpharmforum.org/EN/Index.htm)
- **Western Pacific:** WPPHarm Forum (est 2001); [www.wppf.org/](http://www.wppf.org/)
- **Eastern-Mediterranean:** EmroPharm Forum (est 2002); <http://emropharmweb.com/>
- **Africa:** APForum (est 2004);

63

## African Pharmaceutical Forum (APF)

### New Office Bearers

The annual general meeting held on Tuesday 4<sup>th</sup> August 2007 saw the election of new office bearers. Azubike Okwor took over from Mabel Torongo, the pioneer President of the forum.

Other members of the executive are as follows:

Frank Boateng	VICE PRESIDENT
Mamodou Ndiade	EXECUTIVE MEMBER
Jocelyn Chaibva	EXECUTIVE MEMBER
Didier Mouliom	LIAISON OFFICER
Elijah Mohammed	EXECUTIVE SECRETARY

### Relocation of Secretariat

Annual General Meeting in China approved the relocation of the secretariat of the APForum to Lagos, Nigeria following a long standing request by the Pharmaceutical Society of Nigeria to host the regional body.

The Pharmaceutical Society of Nigeria has since made good their pledge by providing a two room office for APForum at the Pharmacy House located in 32, Faramobi Ajike Street, Anthony Village, Lagos Nigeria.

The Society also donated computers and other office equipment to APForum.

### Activation of an E-Mail Address

APForum has now a functional secretariat with a volunteer Ms. Jean Onoh as office assistance. The forum mail address is [africapharmforum@yahoo.co.uk](mailto:africapharmforum@yahoo.co.uk).

### Publication of an Action Plan

The forum has articulated and published a comprehensive action plan for its subscribing members. The vision of the forum as captured in the document includes the following strategies.

- Mobilizing pharmacists and pharmacy associations in our region to the new paradigm shifts in pharmacy practice and working to equip pharmacist to meet the new challenges.
- Work with WHO, Afro region and the country offices to identify local health needs and act in partnership with other stakeholders to address these needs
- Plan and execute national and regional projects that will have direct impact in improving pharmacists roles in healthcare delivery.
- Act as regional advocates for improved pharmacy practice and rational drug use in our region, this reducing the migration of pharmacists from our region to more endowed regions.
- Provide training and retraining programmes for pharmacists in our forum with a view to improving their skills and knowledge.

### Highlights include initiatives targeted as follows:

- Mobilizing the full membership strength of our forum
- Marking WHO World Disease state days
- Regional seminars and workshops
- Publication of "The African Pharmacist"
- Special Projects/Assignment
- Combating Counterfeit Medical Products
- Collaboration between National Associations
- Pharmacy Self Care Project

## WHO Disease State Days

Within the period under review, the APForum in collaboration with two National Associations celebrated the World Tuberculosis Day on 24<sup>th</sup> March 2008 and World Malaria Day with activities aimed at educating the public about TB.

Reports from Nigeria and Ghana and Sierra Leone show appreciable successes.

In Nigeria the Association of Community Pharmacists of Nigeria (ACPN) mounted a very success market campaign on the burden of malaria in our region.

## West African Post Graduate College of Pharmacists (WAPCP) Scientific Congress

APForum was represented at the 2008 Scientific Congress of the WAPCP.

The meeting provided an opportunity to promote the APForum and FIP to many of the delegates from English-speaking west Africa.

## Mid Year Seminar

APForum is planning a Mid Year Seminar in Accra, Ghana, on the theme: *PHARMACY PRACTICE: A FOCUS ON PATIENTS CARE*.

The seminar previously scheduled for June 2008 is being rescheduled to hold in July to enable APForum join our French speaking colleagues at the 9<sup>th</sup> Inter Ordre des Pharmacists d'Afrique (IOPA) which will hold in Libreville Gabon from 4<sup>th</sup>-6<sup>th</sup> June 2008. Also the annual national conference of the Association of Community Pharmacists of Nigeria (ACPN) is holding from 9<sup>th</sup> -13<sup>th</sup> June 2008.

Already the forum has received several copies of the book *Developing Pharmacy Practice - a focus on patient care* from the WHO as assistance toward the organizing of the Seminar.

## Medicine for Malaria Venture Initiative

Representatives of African pharmaceutical forum were part of a delegation that met with representatives of medicine for malaria venture (MMV).

The medicine for malaria venture is interested in partnership and offering assistance to those interested in manufacturing malaria medicines in Africa.

## HIV/AIDS Training for Pharmacists

The President of APForum had fruitful meetings with Dr. Rosalyn King of Howard University Pharmacy and Continuing Education Centre HUCE/PACE. Dr. King has offered to assist he forum with technical support in HIV/AIDS training for pharmacists in our region.

The impact of HUCE/PACE in countries like Kenya and Nigeria in bringing Pharmacists as active Participants in HIV/AIDs management and Education are commendable and our aim is to let other Africa countries share from these rewarding experiences.

### **Mapping Of Pharmacy Resources**

A pilot mapping exercise for Pharmacy resources is on-going in Nigeria. The aim of the mapping exercise is to provide ample data on Pharmacy for planning purposes.

The result of the mapping exercise should provide answers to poor data on several key resources in pharmacy.

As soon as the pilot project is completed we intend to request other national association to adopt the designed questionnaire for their use.

### **Annual General Meeting (AGM)**

The annual general meeting of the forum is scheduled to be held on Wednesday 3<sup>rd</sup> September 2008 in Basel, Switzerland.

## **Pharmaceutical Forum of the Americas**

### **Introduction**

The Forum continued to develop its activities aimed at spreading Good Pharmacy Practices, Pharmaceutical Care, information through its independent bulletin and advocacy for the participation of the pharmacists in the health care team to improve people's health.

### **Forum Bulletin**

The bulletin of the Pharmaceutical Forum of the Americas is being published every two months. It contains general information about activities as well as important international news related to medicines and pharmaceuticals, public health and pharmacovigilance. A diffusion strategy is now under development to further enhance the distribution of the bulletin.

### **Pharmaceutical Care in Hypertension Project**

The Forum published the final report of the project. It was developed in Argentina, Uruguay and Paraguay and included 113 patients at the end of the study.

The intervention and the control group presented a significant reduction in the medial arterial pressured compared within groups:

- Intervention group: Initial MAP=107.8 mmHg; Final MAP=101.8 mmHg; p=0.0015
- Control Group: Initial MAP=105.8 mmHg; Final MAP=99.6 mmHg; p=0.0004

Both groups showed a reduction in MAP levels. However, the study failed to prove a significant difference in the magnitude of the reduction between groups. It is supposed that this might be because of a bias as both groups of pharmacists were trained in Pharmaceutical Care.

The reports highlights the fact that even there was no difference between groups, a reduction of MAP was evident and that implementation in the community is feasible. However another randomized study with a larger number of patients would be necessary to determine the impact of the intervention in hypertension management.

## Good Pharmacy Practice

In September last year a Seminar on Good Pharmacy Practice took place in the Dominican Republic. It was the starting point for the development of the project in this country, which had good acceptance from the attendants. Uruguay has made the commitment to assist and support the implementation of the project in the Dominican Republic. PAHO/WHO will be supporting a new meeting and training this year with the cooperation of the Pharmaceutical Association form Uruguay. It is expected that this activity will initiate a process with the involvement of pharmacists and health authorities to improve pharmaceutical practice in the country.

Although the pilot project of GPP in Uruguay with the FIP Foundation support has ended, the Pharmaceutical Association and National Working Group of Uruguay have strengthened the achievements of the previous two years in Good Pharmacy Practice. They have been continuing the development of National Meetings, workshops and individual projects to improve professional practice in the country. The Association also maintains permanent support to the involved pharmacists in order for them to reach their goals.

67

## XII FeFaS Congress in Uruguay

The XII Congress of FeFaS (South American Pharmaceutical Federation) will take place from November 18-21<sup>st</sup>, 2008, in Montevideo, Uruguay. The leading topic of the Congress will be: "Science, technology and Pharmaceutical Services to assure better utilization of medicines by the patient". During the Congress 25 conferences as well as symposia and pre-congress activities will be developed taking into account the reality and challenges of the profession in the region.

## Changes in Forum structure and roles

The authorities of the Forum met on March 28<sup>th</sup> in Asuncion, Paraguay. During this opportunity the committee discussed the reorganization of the relationship with PAHO/WHO. The Pan-American Health Organization/WHO proposed during the meeting a different approach, requesting the Associations to lead the secretariat as a means to enhance the role of the Associations in the conduction of the

Forum. The prospecting of the goals, objectives and the future structure of the organization were discussed. In this frame, actualizations of the statute and a new profile for the Secretariat were proposed. A commission was created during this meeting to evaluate the changes in the statute and the way the Secretariat would be conducted.

## Declaration of the Americas

The Executive Committee of the Forum agreed to subscribe to the Declaration of the Americas. The declaration states a brief diagnosis of the pharmaceutical situation addressing the heterogeneity of pharmaceutical practice in the Region and proposes to improve the quality level of pharmaceutical services, the insertion of the pharmacist in the health team and to promote the practice of pharmaceutical care as a way to collaborate with the improvement of public health. The declaration also requests governments to guarantee pharmaceutical participation in the areas of hospital, community and industrial pharmacy as well as in the fields of regulation and pharmaceutical policies.

## EuroPharm Forum

The EuroPharm Forum is a joint network of national pharmaceutical associations and the WHO Regional Office for Europe. The mission of the Forum is to improve health in Europe according to priorities set by the WHO and to strengthen the position of pharmacists by showing their value to people involved in health issues.

68

### Executive Committee

Inger Lise Eriksen, <i>Norway</i>	PRESIDENT
Henri Lepage, <i>France</i>	VICE PRESIDENT
Ingunn Björnsdóttir, <i>Iceland</i>	
Karin Graf, <i>Germany</i>	
Balázsc Hankó, <i>Hungary</i>	
Th(Dick)FJ Tromp, <i>The Netherlands</i>	

### Main activities in 2007/2008

- October 2007 Annual Meeting comprising a professional session  
The 16<sup>th</sup> Annual Meeting of the EuroPharm Forum took place in Bratislava, Slovak Republic. Sixty delegates, representing 21 member countries, attended the General Assembly to assess the work of the past year, plan future activities and to decide on issues of policy. On the second day of the Annual Meeting, a symposium on migration issues was conducted.
- April 2008 Training Seminar: Implementation Strategies - from Global Health Priority to Everyday Practice

The Training Seminar took place in Copenhagen at WHO Europe. Nearly fifty participants met and were very actively involved in the two-day seminar. Besides learning and working with evidence and implementation processes, participants also joined the professional programme of the EuroPharm Forum and worked in prioritised Working Groups.

## Member countries

Austria	Hungary	Romania
Belgium	Iceland	Serbia
Croatia	Ireland	Slovak Republic
Czech Republic	Italy	Slovenia
Denmark	Latvia	Spain
Estonia	Former Yugoslav Republic of Macedonia	Sweden
Finland	Republic of Moldova	Switzerland
France	Netherlands, the	Turkey
Georgia	Norway	United Kingdom
Germany	Portugal	

## Benefits from membership

### Supporting elements

- Toolbox (CD-ROM) for professional development, containing for example protocols for Tobacco Cessation, Cardiovascular Diseases, Diabetes and Asthma
- Basic documents on the pharmacist as a health promoter
- On-line database of professional activities in member countries
- Web-based discussion fora
- Experience-sharing platform
- Training seminars on various aspects of the implementation and management of pharmacy-based services
- International conferences on issues of policy, ethics and practice

### Collaboration

- Knowledge sharing between members
- Partnership with the WHO
- Partnership with international organisations
- Insight into health priorities set by the WHO

## Professional Programme

The Professional Programme is set up in seven programme areas that reflect WHO priorities. The national associations, through community pharmacies, conduct the Programme. Each programme area seeks to involve pharmacists in WHO efforts to improve patient care and chronic disease management, and support health promotion and wellbeing through lifestyle counselling services.

The Professional Programme deals with

- Safe Medication Practices
- Chronic Diseases
- Prevention of Non-communicable Diseases
- Communicable Diseases
- Quality
- Palliative Care
- Education.

Within each specific area of the Professional Programme, the various subjects have been grouped according to status and priority in the EuroPharm Forum, cf. table.

High priority	Cancer	Education	Health Systems	Obesity	Quality of Medicines	Mental Health	Pandemic Influenza	Safe Use of Medicines
<b>Mature</b>	Asthma	Cardiovascular Diseases	Diabetes	HIV/AIDS	Self Medication	Tobacco		
<b>Dormant</b>	Alcohol	Antimicrobial Resistance	Information Systems	Screening	Sexually Transmitted Diseases			

High-priority Working Groups were given special attention in 2007-08. They will map, as a first step, pharmacist activities connected to the Working Group issue and to the creation of partnerships. As for Working Groups with mature status, members are encouraged to make use of the model programmes already available. The dormant Working Groups were given low priority in 2007-2008.

#### More information

Please visit our website: [www.europharmforum.org](http://www.europharmforum.org)

## South-East Asia (SEARpharm) Forum

### I. Activities

#### WHO-FIP guidelines for GPP

Report on First Regional Conference on GPP Policy and Plans for the South East Asia Region, Bangkok, Thailand, June 27 - 29, 2007

A Conference was organized by SEARPharm Forum with support from the FIP Foundation, WHO-SEARO, WR Thailand, Thai FDA and the Thailand Pharmaceutical Association to discuss the Good Pharmacy Practice (GPP) development, policy and plans in the SEA Regional countries with Thailand as a project country. A few Western Pacific Pharmaceutical Forum (WPPF) countries were also invited to share their experiences. The objective of the Conference was to promote the development of GPP in the Region since GPP is an important component for raising standards of pharmacy services and practice as well as professional attitude and behaviour of pharmacists for improving health in the community.

The Conference was attended by 56 pharmacists from 15 countries representing practice, Government, academia and national pharmaceutical associations. The resource persons were present from the FIP, WHO-SEARO and Western Pacific Pharmaceutical Forum.

The three day programme began with an assessment of GPP status in seven countries of the SEA Region and three countries of WPPF to determine a unified GPP mobilization direction at both country and regional levels. The self-assessment of countries brought out obstacles and inconsistencies in implementing GPP in the SEAR countries thereby sub-optimizing the role of pharmacist in health care in the Region. A number of issues were identified, such as, lack of competency, traditional and short term thinking, good intentions but not able to implement, shortage of availability of pharmacists and lack of resources etc. Thereafter, priorities for interventions e.g. country specific activities, assistance needed and self-development initiatives were identified. As a case study, the participants were familiarized with the outcome and experiences of the FIP/WHO GPP outreach project in Thailand. This project has led to implementation of a policy of accrediting pharmacies in Thailand by Thai FDA with the support from Thai Pharmacy Council and universities. The participants were also provided an opportunity to visit some accredited pharmacies in Bangkok. During the Conference, the Thai Pharmaceutical Association organized dinner talks on "Development of GPP - FIP approach" and "Evidence for GPP in promoting drug access and healthier life". At the end of the conference, the following six priority areas emerged:

- Changing perception of the role of pharmacist among themselves
- Improving quality of pharmacy practice
- Documentation and dissemination of the value and benefits of pharmacy in supply chain for society and for the patients
- Raising public awareness of the added value of the role of the pharmacist/ pharmacy
- The role of the pharmaceutical associations and Regional Forums
- Education and continuing education

71

A brainstorming session led to identification of activities which participants will undertake to implement GPP in their countries in a time-bound manner and in doing so, further identification of individual country needs and support is required. The member Countries urged FIP, WHO-SEARO and local governments for technical assistance and resources for implementation of GPP at national levels.

A highpoint of the conference was adoption of "Bangkok Declaration on Good Pharmacy Practice in the community pharmacy settings" in the SEA Region.

### **Challenges and Opportunities for pharmacists in health care in India**

A National Conference on Challenges and Opportunities for Pharmacists in Health Care in India was held in New Delhi on 30 October 2007 by the SEARPharm Forum in collaboration with WHO-India. The aim of the Conference was to deliberate the role of the pharmacists:

- As a knowledge worker in 21st Century in community, hospital and government practice settings
- As a health worker in Rural and Public Health
- As a health care professional in improving access to medicines

Historically, the potential of pharmacists in community, hospital and government practice settings is not fully utilized in India. The pharmacists are seen as business people. The professional role of the pharmacist is not projected in the Government's health and pharmaceutical policies. This conference examined various issues, shared experiences and evidences of pharmacists' involvement in national health programmes for improving pharmaceutical care and rolled out strategies for integrating

pharmacists as team members with other health professionals. Strategies were also outlined for the future role of pharmacists beyond supply of medicines, much needed educational reforms and stakeholders' involvement. The lead authors and experts prepared the position papers. Distinguished guests, speakers from the Planning Commission, National Rural Health Mission, Revised National TB Control Programme, Rollback malaria, Family Planning, National AIDS Control Organization and access to essential medicines and rational use of drugs through pharmacists, shared their views on challenges and opportunities for pharmacists. The full report can be downloaded from [http://www.whoindia.org/LinkFiles/Essential\\_Drugs\\_and\\_Medicines\\_Report\\_on\\_CO\\_for\\_Pharmacists\\_in\\_HC\\_in\\_India.pdf](http://www.whoindia.org/LinkFiles/Essential_Drugs_and_Medicines_Report_on_CO_for_Pharmacists_in_HC_in_India.pdf) or [www.searpharmforum.org](http://www.searpharmforum.org).

### **Combating the menace of counterfeit medicines and sale of medicines by persons who are not qualified**

*A Model to Estimate the Extent of Counterfeit Medicines in India (Based on "A Survey on the extent of counterfeit medicines in India")*

Various estimates have been made about the extent of counterfeit drugs in India. However, no systematic study has ever been undertaken to generate credible data. This has led to speculative and magnified figures in press.

What makes the problem more intriguing is that counterfeit medicines may comply with quality standards. They imitate popular brands. Counterfeit medicines circulate in complex distribution systems permitting buying and selling among agents, wholesalers and retailers, all who may be hiding real from fake.

In November 2003, an Expert Committee headed by Dr. R. A. Mashelkar recommended that the MoH undertake a study based on the Delhi Pharmaceutical Trust's proposal which was scientific and statistically designed to obtain a clearer picture on the extent of spurious drugs in India. SEARPharm Forum (WHO-FIP Forum of National Pharmaceutical Associations of South East Asia Region) conducted the study with technical assistance from Apothecaries Foundation which conceptualized the study model and prepared protocol. The World Health Organization's South East Asia Regional Office supported the study.

The domestic sale in 2006 is estimated to be USD 7 billion. Approximately 70% of this sale is realized from the retail market.

This Survey is based on 10,743 samples collected from 234 retail outlets in metros and district headquarters spread over 38 locations in 15 states in 5 regions through out the country. The locations were chosen based on perceived regulatory status.

Medicines from 56 top selling brands covering 12 therapeutic categories with prices varying between less than USD 0.5 to more than USD 12.5 were selected.

Mystery/surrogate patients posed as customers and purchased medicines against prescriptions from retail outlets near government hospitals, railway stations, bus stands in market places. Suspected counterfeits were isolated by trained professional based on visual inspection as first inference of unusual appearance and subsequently, subjected to laboratory analysis by accredited laboratories.

Based on the visual inspection, the extent of counterfeit suspects was to the tune of 3.1 per cent and would be extrapolated to USD 250 million. These figures are much lower than various reports of spurious drugs at around USD 1,000 million. It was interesting that even from states perceived to be

strongly regulated, the percentage of counterfeit suspects is almost same as weakly regulated (3.3 Vs 3.5 %). The data showed Bihar having highest probability of counterfeit suspects in the country.

Contrary to the belief that high cost medicines are more prone to counterfeiting, the findings showed that medicines in price range of less than USD 0.5 were maximum targets for counterfeiting. The high and low incidents of suspected counterfeits were found in anti-histamine and cardio vascular drugs respectively. No suspects were identified among anti-TB drugs. The failing samples were all from anti-infective category further substantiating the results of the earlier international study published in lancet that anti-infectives were prone to counterfeiting.

While this model study covered the extent of counterfeit drugs available through retail outlets, it would be worthwhile to explore the extent in other distribution channels, inter country commerce and individual therapeutic categories. Another application of this study model would be in the training of consumers, drug procurements agencies and chain pharmacies against the menace of counterfeit medicines.

#### **Database on incidents on counterfeit medicines in SEA Region: 2007 update**

It is perceived that the incidents of counterfeit medicines are increasing in the SEA market. However, there is no reliable data on such incidents. The SEARPharm Forum Secretariat collects information on the prevalence of counterfeit medicines as reported in local newspapers/journals/weeklies. This is an on going activity of the Forum. The Forum intends to continue building up this database further. The updates are available on SEARPharm Forum website.

#### **Emphasizing Pharmacists role in prevention of HIV/AIDS**

Guiding Principles for Pharmacists: HIV/AIDS in India

The SEARPharm Forum has revised the FIP-CPS sponsored publication "Guiding Principles for Pharmacists: HIV/AIDS in India". The revised publication can be downloaded from SEARPharm Forum's website ([www.searpharmforum.org](http://www.searpharmforum.org)).

#### **CPA-PSSL Workshop on pharmacists role in the prevention and management of HIV/AIDS and TB - Sri Lanka**

A PSSL-CPA interactive workshop was held during 38th Anniversary Sessions of Pharmaceutical Society of Sri Lanka in May 2007 in Colombo, where the Professional Secretary of the Forum, Mr. Prafull D. Sheth chaired a session during the workshop. The workshop explored:

- What challenges do pharmacists face in providing HIV/AIDS and TB Services?
- How can pharmacists take a proactive role in meeting these challenges?
- Challenges and strategies.

#### **Curriculum reform at all levels in Myanmar and Nepal**

- Curriculum upgradation in Myanmar
- Myanmar is upgrading curriculum for pharmacy education. Syllabus copies of various Indian Universities and FIP documents on Pharmacy Education were supplied to Dr. K. Weerasuriya, Advisor EDM, WHO-SEARO for updating the Pharmacy curriculum and for onward transmission to Myanmar.

#### **Curriculum upgradation in Kathmandu University**

Kathmandu University, Nepal has revising pharmacy curriculum at all levels. Syllabus copies of various Indian Universities were sent Assistant Professor, Department of Pharmacy, Kathmandu University, Nepal.

### Technical inputs on pharmaceutical issues to WHO-SEARO

In December 2007, Forum provided technical support on specifications and prices of hardness, disintegration and friability testing apparatus for DPR Korea.

In November 2007, Forum provided technical support on reference standards on Miazee Starch, Talc and Isopropyl Alcohol.

In September 2007, a list of manufacturers for Folic acid and Calcium lactate were provided for WR-Sri Lanka.

In April 2008, provided technical support on disposal of large quantities of diethyl carbamazine citrate (DEC) tablets in Nepal.

## II. News Highlights

The Forum's ExCo meeting during the First Regional Conference on GPP Policy and Plans for the South East Asia Region, Bangkok, Thailand, on 26 June 2007 was held. Dr. Peter J. Kielgast, Mr. Kurt Fønnesbek Rasmussen, Professor Th (Dick) F J Tromp, Mr. Xuanhao Chan were present from FIP.

In pursuing the GPP Bangkok declaration, two GPP Training workshops were held in Bhutan from 16-18 Jan 2008 (1st batch) and 12-14 Feb 2008 (2nd batch) to implement GPP in the country with support from DRA Bhutan and Health Services, National Essential Drugs Programme, Bhutan. Pharmacy personnel working in all government sectors of pharmaceutical services such as hospital, regulatory agency, drug supplies management, production and quality assurance were the target audience for the workshops.

### FIP Travel Grants for 2008

Based on the recommendations of Forum, the grants for the year 2008 have been awarded to 1. **Ms. Yulia Trisna** (Indonesia); 2. **Ms. Pooja Borker** (India). The Forum is grateful to FIP for these travel grants.

74

## II. News Highlights

Design and develop awareness campaign material to educate pharmacists and consumers about counterfeit medicines

The SEARPharm Forum concluded "A survey on the extent of counterfeit medicines in India" in May 2007. One of the applications identified in the report is its usefulness to create awareness among the pharmacists and consumers on the menace of counterfeit medicines and sale of medicines by people who are not qualified. The awareness campaign will be based on guidelines for physical inspection of formulations used in the survey. The Forum intends to supply the campaign material to the National Pharmaceutical Associations for use in their countries with a request that campaigns be organized against menace of counterfeit medicines. Similar campaigns organized in partnership between the Ordre National Des Pharmaciens and the French Agency for the Safety of Health Products (AFSSAPS) to inform pharmacists and the public on the risks of counterfeit medicine are found to be very effective in France.

As a follow up and review the progress made on GPP implementation in member countries, a 2nd Regional Conference on "GPP Policy and Plans for the South East Asia Region" is being planned at Indonesia Pharmacist Association hosting at Yogyakarta, in August 2008.

During the 2nd Regional Conference on GPP, the Forum is planning to hold its Annual Meeting during which the SEARPharm Forum Executive Committee elections are due for the period of 2008-2010.

SEARPharm Forum is planning a joint seminar on GPP with Western Pacific Forum in November 2008 during the FAPA Congress in Singapore.

## Western Pacific Pharmaceutical Forum

### Summary

Changes to the practice of pharmacy still continue at a great pace, particularly in relation to the separation of prescribing and dispensing. These are taking place within the backdrop relating to changes taking place in the powerhouses of China and Vietnam. Japan, China Taiwan, the Philippines and Korea have undergone many changes. Japan, Australia and New Zealand are making enormous strides in developing cognitive services offered by pharmacy.

China Taiwan is reviewing ways and means of introducing these cognitive services into their practice. The China Taiwan Department of Health sent a team to Australia to investigate HMRs and a selected speaker was subsequently invited to address pharmacists in China Taiwan.

Through its Bureau of Drug Administration the government of Vietnam continues to move forward with its master plan strategy to completely change the method of distribution of medicines in Vietnam by 2010. The project is being conducted to ensure sufficient supply of quality medicines and their rational safe use.

The Forum has continued to strengthen its links with Mongolia, Cambodia and with Papua New Guinea. Papua New Guinea has, for the first time in history, developed a national Pharmaceutical Society for that country.

Following our visitations to many hospital pharmacies in the region over the last 12 months, the Forum is instituting a program to encourage hospital pharmacists in the Western Pacific region to establish a consultative network for communication and interaction between each country.

The Forum is encouraging and promoting pharmacists in the Western Pacific region to support the special seminar in Basel on the future of hospital pharmacy practice.

### Meetings

Meetings of the Executive Committee were held in Manila, Philippines; Hanoi, Vietnam and Melbourne, Australia. The members of the Executive committee are:

John Ware OAM, <i>Australia</i>	PRESIDENT
Wai Keung Chui, <i>Singapore</i>	VICE-PRESIDENT
Nobuo Yamamoto, <i>Japan</i>	
Tony Tarn, <i>China Taiwan</i>	
Eun Mi Kim, <i>Korea</i>	
Reynaldo Umali, <i>the Philippines</i>	
Jane Ho	IPSF OBSERVER

## Review of Western Pacific Region, Schools of Pharmacy

The Forum has followed up this successful publication with a CD of the Review of Pharmacy Schools and Pharmacy Undergraduate Education, Registration and Licensing Requirements in the Western Pacific Region with a further questionnaire to determine whether or not undergraduate curriculum is determined by standards of competence.

Wherever Forum meetings are held, the Executive undertakes visitation to the schools of pharmacy and seeks meetings with the academics involved.

The Forum has commenced a program to develop a network of academic pharmacists within the Western Pacific Region. A request has also been made to the World Health Organization to arrange another meeting of pharmacists and academics within the region to discuss curriculum and competency standards. This would be a sequel to a meeting sponsored by WHO held in Malaysia some years ago. As in the previous meetings, its intention is that it should be a joint meeting between the Western Pacific regional office of WHO and the SEARO region of WHO. A firm proposal on this matter is being put to the Western Pacific Regional office.

## Interaction with the World Health Organization

Dr Budiono Santoso, Pharmaceutical Advisor, Western Pacific Regional Office of WHO is a regular attendee of meetings of the Forum and is frequently accompanied by other members of his staff who have areas of special interest. This is helping to create a greater understanding in his department about the work of the Forum. It is of note that the minutes of the last Executive committee meeting record that Dr Santoso in addressing the Forum, expressed his thanks and appreciation of the work that was being undertaken in support of WHO's objectives in pharmaceuticals in the Western Pacific region.

76

## Western Pacific Pharmaceutical Forum Scholarship Trust

The purpose of establishing this trust was to encourage travel of senior pharmacy students and young pharmacists within the region, either as interns with WHO or supporting work in developing countries.

The development of the trust has been held up due to the problems in establishing a satisfactory banking arrangement. If this problem persists, it is the intention of the Forum to undertake discussions with the chairperson and CEO of the FIP Foundation for Education and Research to see if some co-operative movement might be established.

## Restructuring Pharmacy Practice in Vietnam

This has probably been one of the largest projects undertaken by the Forum at this stage. Following a request from the State Drug Administration of Vietnam and with support from the Pharmaceutical Association of Vietnam, the Forum has undertaken the following projects in relation to good pharmacy practice in Vietnam.

- The Western Pacific Pharmaceutical Forum, at the request of the government of Vietnam developed draft GPP statutes for the Drug Administration of Vietnam. These statutes were adopted by the Department of Health of Vietnam and passed into statute law in 2007.
- The Forum developed checklists for GPP statutes in Vietnam
- WPPF, with financial support from the World Health Organization and lecturers from the National University of Singapore and Monash University Australia, conducted 'train the trainer' programs in Hanoi and Ho Chi Minh City, training 140 pharmacists in Vietnam to train others in the GPP statutes and requirements. The Forum expects the Pharmaceutical Association of Vietnam as well as the Drug Administration Vietnam to conduct further training programs so that all pharmacies in Vietnam can be brought up to the standards of the new statutes by 2015.

In the major cities of Vietnam, Hanoi, Ho Chi Minh City, Hue, Cantho etc, the government is determined to reach the standards by 2010. Pharmacies not reaching the required standards will be required to close.

### **WPPF Website**

The website, under the guidance of Executive member Dr Tony Tarn and his advisory committee, continues to develop under the new leadership of Managing Editor, Ms Jane Ho. The website was formerly managed by Ms Katrina Chou, who has now moved on in her role and expresses thanks to Katrina for her work.

The website has been restructured considerably with an education program having been added to the material and of particular note was having President Midha's address in Beijing translated into Mandarin, Japanese and Korean for publication within the region.

A new method of promoting the website has commenced with an e-letter being sent monthly to all organisations and interested parties within the region, referring them to the website.

A new interactive section of the website is being developed particularly for hospital pharmacists.

### **FIP Congress Beijing China**

The President of the Forum was invited to address members of the FIP Council and observers on the topic 'How Can a Forum Enhance Pharmacists' Roles and Impact'.

### **General Programs**

The Forum continues to support and encourage promotional programs regarding counterfeit medicines, 'ask questions about your medicines' and smoking cessation programs within the region.

### **Meetings Attended for Forum Representation**

- The 150<sup>th</sup> Anniversary celebration of the Pharmaceutical Society of Australia (Victorian Branch)

held in conjunction with the Pharmacy Australia Congress in Melbourne, August 2007. The Forum wishes to express its appreciation to the Pharmaceutical Society of Australia in hosting the members of the Forum during an Executive meeting prior to the Congress and celebrations and hosting the Executive throughout that meeting.

- General Secretary, Reynaldo Umali, represented the Forum at the regional meeting of health ministers of the Western Pacific region, in Korea
- The President, John Ware, attended and addressed the IPSF annual conference in Taipei, China Taiwan.
- The Annual General Meeting of the Forum was held in Hanoi, Vietnam in October 2007.

The Forum continues to appreciate the support of our member organisations as we try to create better regional links to FIP and between our associations in the Western Pacific region.

Our objective is to encourage and stimulate an easy dialogue and a true understanding of each other's practice.



# FIP Young Pharmacists Group

## The YPG is a network inside the International Pharmaceutical Federation (FIP)

The YPG represents *pharmacy practitioners* and *scientists*, members of the FIP who, because of their age and/or status as recent graduates, occupy a specific niche in the profession. The mission of the YPG is to help develop individuals who can act as agents of positive change at local, national and international levels, both in the profession and in society. It acts as a member-to-member gateway to FIP activities, creating opportunities by exchange of information.

## Organisation

The 2007-08 Steering Committee was elected during the 2007 FIP Congress in Beijing, China:

Gisselle Gallego, *Australia / Colombia*

CHAIR

Hugo Figueiredo, *Switzerland*

PROJECT COORDINATOR

Halil Tekiner, *Turkey*

PUBLIC RELATIONS OFFICER

## 67<sup>TH</sup> FIP CONGRESS BEIJING, CHINA, 2007

79

The YPG hosted three educational and two social events during the 2007 FIP Congress in Beijing, China. This important but somehow unaddressed subject "*Financing Healthcare*" was the 2007 YPG educational forum topic. A joint session with the IPSF and the Community Pharmacy Section was also held. For the first time a new format was introduced in this joint symposium. Four contentious community pharmacy topics were chosen: collaborative practises, deregulation of the pharmacy practice, leadership and specific roles for the community pharmacists in the healthcare team. The last event was a joint symposium with the Pharmacy Information Session entitled "Good versus bad drug information in the public domain - can you spot the difference? Empowering pharmacists and educating patients how to use online information". Two social events including a YPG welcome dinner and an International Night party were organised together with the International Pharmaceutical Students Federation (IPSF).

## 68<sup>TH</sup> FIP CONGRESS BASEL, SWITZERLAND, 2008

The topic for the 2008 YPG Educational Forum is "*The role of pharmacists in primary health care*". This forum will debate the barriers and facilitators posed to pharmacists in the developing world and the importance of primary healthcare. A joint session with the Community Pharmacists Section (CPS), the International Pharmaceutical Students' Federation (IPSF) and YPG is also planned. The joint symposium will highlight "*Trends in Community Pharmacy - Debating the Future of the Profession*". The event is planned as a debate around three central topics which we believe will be playing significant

roles - both positive and negative - on the profession. These include: changes in regulatory classification of medicinal products - Lessons learned and the role of the community pharmacist in rational drug use; direct to consumer advertising; and changes in drug supply - Direct to consumer and new channels of distribution.

YPG will be also hosting two networking events for congress new-comers and young pharmacists. These are the YPG Welcome Dinner and the YPG/IPSF International night. The Swiss Young Pharmacists group has been liaising with us to coordinate these events.

## Communication

The YPG maintains two major routes of communication with members: a members-only list serve, and an e-group open to both members and non-members. By spring 2008, the list serve facilitated communication with our 550+ members and the e-group connected 1390 pharmacists worldwide. The first YPG e-newsletter was produced and emailed in December 2007. The second e-newsletter was sent to the YPG e-group in mid February 2008. The YPG subcommittee expects to produce two more e-newsletters.

## Other YPG Activities

FIP members from Finland, India, Pakistan, Portugal, Uganda, USA and Zimbabwe answered to the 2007 **Young Pharmacists/ Pharmaceutical Scientist Grant for professional innovation** call for applications. The 2007 grant was awarded to Christie Robinson, a clinical pharmacist from the United States. Christie's project seeks to enhance health literacy of indigent HIV-positive people through the provision of Consumer Internet Health Education. The Board of Directors of the FIP Foundation for Education and Research supported and presented the monetary sum of € 1 000 to complete her project. She will attend the 2008 FIP Congress in Basel and officially receive the Award.

Answering the 2008 call for applications, grant proposals were received from Australia, India, Nigeria, Pakistan, Peru, Portugal, Puerto Rico, Switzerland and Zimbabwe. The proposal ranged in scope from pharmacy profession and politics, drug metabolism, natural medicines to nanotechnologies. The winner is to be announced in June 2008 and the award will be presented during the Istanbul 2009 congress.

The FIP Industrial Pharmacy Section, International Pharmaceutical Students' Federation and YPG **Mike Howe Award for Young Professionals and Pharmacy Students** was presented for the first time during the 67th FIP Congress in Beijing, to support individuals involved in the development, manufacturing and regulatory aspects of Pharmaceuticals. The 2007 award recipient was Mr. Uttam Budhathoki. Uttam is a Nepalese pharmacist who is currently studying towards a PhD. According to Uttam the Mike How Award allowed him to fulfill his dream of participating in FIP congress.

The Young Pharmacists Group in partnership with one of the British pharmacy organisations, the Pharmaceutical Services Negotiating Committee (PSNC) finished the third and last season of the Global WEBlogs project. The 2007 bloggers came from seven different countries (Australia, Ghana, India, Sweden, Switzerland, Uganda and USA). They told us about their jobs, pharmacy practice in different countries and the challenges of pursuing a postgraduate degree. The 2007 Weblogger was Stephen Mawa, a research pharmacist in several HIV vaccine clinical trials in Uganda. Last year he set up a community pharmacy in a rural underserved part of Uganda.

## Developing Opportunities

The YPG has been working with the FIP Community Pharmacy Section, to encourage innovative community pharmacy projects, initiated and run by young pharmacist. The first project supported by the CPS was developed by Ms Katja Hakkarainen a young pharmacist from Finland. Katja's project aims at defining the concept of "medication review", a form of cognitive pharmaceutical service, through a narrative literature review and a qualitative document analysis of legislation on medication reviews. Katja will also be a speaker for the "*Medicines Information for Patients*" CPS symposium in Basel.

Recently the Administrative Pharmacy Section offered the opportunity for three enthusiastic young pharmacists to work on the Project Team implementing the International Survey of Pharmaceutical Policy. Nine YPG members answered the call and applied for these volunteering positions; three were chosen.

The Community Pharmacy Section and Pharmacy Information Section have expressed their interest in engaging more young members in 2008. We expect to strengthen the relationship with other FIP Sections and SIGs and allow the integration of YPG members into the Federation. The YPG Steering committee is also actively working to identify better avenues for promoting the FIP/YPG among young pharmacists around the world

The FIP Young Pharmacists Group is pleased with the growing membership and support. YPG represents the international pharmacy leaders of tomorrow and we frequently receive inquiries from members about avenues to get actively involved. The FIP Young Pharmacists Group strongly encourages FIP member organisations to create and/or support the development of new practitioner or young pharmacist networks. These networks will enable Member Organisations to meet the needs of this unique niche and foster development of the pharmacy leaders of tomorrow.







# FIP and WHO: FIP expands at home and abroad

## A Message from the FIP General Secretary Mr A.J.M. Hoek

The 2007-2008 year was a time of significant expansion for FIP, both figuratively and literally. Over the past 12 months the Federation has continued to grow in ideas, projects and scope and to foster current and new partnerships, elevating FIP to a level of true influence on the global pharmacy and healthcare stage. FIP is talking and people are listening; we are taking action and others are noticing. To signify these developments and to solidify FIP's dedication to their future progress, the Spring of 2008 saw the establishment of the first off-site FIP office, implemented to increase communication and interaction with WHO and other partners in and around Geneva, Switzerland.

With this development, we hope not only to increase our own involvement in issues shaping the pharmacy profession, but that of our collaborators as well. In May of 2008, preceding the World Health Assembly, FIP and its partners in the World Health Professions Alliance hosted the first World Health Professions Conference on Regulation. This meeting examined regulatory issues affecting the practice of healthcare, and how health professionals can and should be involved in a collaborative, multi-disciplinary level in order to steer regulatory authorities to clear and effective healthcare guidelines.

Our direct work with WHO also continues to grow. In February 2008 FIP and WHO co-organised the First Global IMPACT Forum, bringing together for the first time Regulators and Industry to discuss how collaboration between the two groups can more effectively fight counterfeit medicines. This was complementary to the Federation's ongoing work in the WHO IMPACT Working Group on Communication and our internal priority of raising awareness of Counterfeit Medicines amongst our Members.

The FIP Pharmacy Education Taskforce is also moving forward in great strides, with a proposed Tripartite agreement between FIP, WHO and UNESCO. The agreement will in essence leverage the respective strengths and expertise of each sector - education, health and professions - to enable achievable and sustainable workforce development. The Taskforce will convene for the 3rd Education Roundtable at the 68<sup>th</sup> FIP Congress in Basel, Switzerland to discuss the potential of this new agreement and ongoing initiatives.

A detailed report of our ongoing collaboration with WHO will follow this introduction. In it we are pleased to bring you updates of how FIP and its officers are contributing to significant, global developments in healthcare.

Mr A.J.M. Hoek  
*FIP General Secretary*







# WHO-FIP

## Status Report

### January 2007 - April 2008

## Projects

- FIP and WHO have published the WHO/FIP *Developing Pharmacy Practice: a Focus on Patient Care, Booklet 2006 Edition*. This manual will serve as a tool and a guide for pharmacy training, both in industrialized and resource-constrained countries. A process of field testing has been initiated and will be continuous through 2007/2008. FIP has also been actively promoting the publication in its Boards.
- FIP released a Press Release on 7<sup>th</sup> April, World Health Day 2007, emphasising on the value of pharmacists, being the most accessible health care professional, in responding to emergencies. By focusing on knowledge, preparation and communication, pharmacists will have the tools to respond in times of crisis.
- FIP contributed to the report on the WHO/NGO workshop on health promotion and the NGO Action Plan to implement the Bangkok Charter on Health Promotion. FIP is represented in the Steering Committee of the WHO NGO Advisory Group on Health Promotion since February 2006 and has been active in developing the booklet *From Vision to Action*. An NGO briefing will be organised in the World Health Assembly 2007 focusing on Integrative Primary Care, a role for NGOs in bridging the gaps in health promotion.
- FIP has progressively increased its collaborations with the WHO Human Resources Department since the WHO World Health Report 2006 and toolkit. Our contributions in Human Resources for Health:
  - Formation of a FIP-WHO Pharmacy Education Taskforce. A committee has been established with experts in the field along with representation from WHO. A two year action plan has been developed following the 2006 roundtable consultation which has been formally approved by both FIP and WHO. Funding is being sought to implement the plan.
  - FIP has joined the Global Health Workforce Alliance (GHWA). A representative of the FIP-WHO Pharmacy Education Taskforce will be invited to join the technical group on scaling up training and education.
  - FIP together with WHPA partners, WHO, GHWA and other organisations organised an International Health Workforce Conference in Geneva which was held 22-23 March 2007.
  - FIP-WHO Pharmacy Education Taskforce will organise the second round table for Pharmacy Education at the 67<sup>th</sup> FIP Congress in September 2007.
  - FIP lead the launch of the Global Tripartite Education Action Plan 2008-2010 with WHO and UNESCO at a joint session held at the Global Health Workforce Alliance Forum for Human Resources for Health in Kampala, Uganda, 6 March 2008.

- The Action Plan focuses on addressing bottleneck issues in pharmacy education such as academic and institutional capacity, quality assurance, vision and competency. The joint effort of these organizations facilitates a more effective, efficient and concrete approach as well as enabling a multi-sectoral platform for dialogue, learning and sharing of evidence and experience at global, regional and local levels.
- As part of the consultative process on pandemic influenza ethics with the WHO Department of Ethics, Trade, Human Rights and Health Law's (ETH) cooperation with the Department of Epidemic and Pandemic Alert and Response (EPR), a FIP representative will join the Working Group Three (Ethical Issues Associated with the Roles and Obligations of Health Care Workers).
- FIP has been invited to attend the resumed second session of the Intergovernmental Working Group on public health, innovation and intellectual property at CICG Geneva, 28<sup>th</sup> April to 3<sup>rd</sup> May 2008.
- Since the inception of WHO International Medical Products Anti-Counterfeiting Taskforce (IMPACT) in Rome, February 2006. On behalf of the WHPA, FIP has taken a lead role in the WG Communications in IMPACT and will be driving forth the risk communications strategy for counterfeit medicines globally. The next General Meeting of IMPACT is planned for in November 2008.
- FIP co-organised the FIP/IMPACT meeting on using technology to combat counterfeit medicines in Singapore, February 2008. This meeting brought together drug regulatory authorities and technology developers from about 40 countries. FIP is currently hosting [www.impactglobalforum](http://www.impactglobalforum) for communications on IMPACT activities. FIP will also be taking a lead in drafting the next IMPACT document on Internet Pharmacy.
- FIP was invited to participate in a communications review meeting of the World Alliance on Patient Safety. Updates were received on the first and second Global Patient Safety Challenge, on Clean Care is Safer Care and Safe Surgery. The next patient safety challenge is to focus on antibiotics resistance in 2009-2011.
  - FIP participated in the field review of 'Patient Safety Solutions' developed by the WHO collaborating centre on Patient Safety with input from members of the patient safety working group in February 2007.
  - Following a meeting held in 2006 to discuss collaborative plans, FIP is undertaking a project on medication error reporting systems with input from the Alliance. A report is due in June/July this year and will also be disseminated to the Alliance.
  - FIP and the Alliance will be meeting during the WHA to explore a collaborative programme of work for 2007-2008.
- FIP is an official Partner of the *WHO Partnership for Maternal, Newborn and Child health (PMNCH)* and was represented in the first Partners' Forum in Tanzania, April 2007 by the president of the Pharmaceutical Society of Tanzania. FIP continues to advocate a role of the pharmacist in maternal, newborn and child health care.
- FIP remained in close communication with the *WHO HIV/AIDS* Department. FIP was invited to the 9<sup>th</sup> Technical consultation on WHO global recommendations on task shifting, with special regards to the HIV/AIDS situation. Appropriate interventions were delivered by FIP. Subsequently, FIP was invited as a partner in the Addis Abba launch of these recommendations in January 2008.

- WHO is revising the WHO Guide on Multisource (Generic) Pharmaceutical Products: Guidelines on registration requirements to establish interchangeability. A FIP/WHO Biopharmaceuticals Classification System (BCS) Task Force has been established and the FIP Board of Pharmaceutical Sciences has continued to be instrumental in the revision process of these guidelines.
- FIP worked with the WHO Traditional Medicines Department for the 67<sup>th</sup> International Congress of FIP in Beijing, China, 2007, which themed on various aspects of traditional medicines in patient use and healthcare systems. For the first time, the professional symposia of the FIP Congress was co-sponsored by the WHO. FIP co-organised a WHO/FIP workshop on herbal medicines: Education and training of pharmacy practitioners in Beijing.
- FIP is invited to the WHO Working Group meeting on preparatory organising committee of the WHO Summit Congress on Traditional Medicines and will explore potential increased visibility of FIP in the realm of traditional medicines. FIP has been invited to nominate 5 representatives to the WHO Governmental Forum in the WHO Congress on Traditional Medicines in November 2008. In this congress, FIP will organise a joint symposium on traditional medicines with the World Self Medication Industry.
- FIP will be working together with WHO and the World Federation of Medication Education to establish a database of health training institutions, including pharmacy schools in 2007. FIP will a formal partner in this initiative and be invited to join the board. The FIP Academic Section is working together with the WHO Human Resources Department and WFME on this project. FIP has initiated a process of updating its World List of Pharmacy School database since Feb 2007.
- FIP-BPP Counterfeit Project was initiated in collaboration with WHO in 2003. The goals of this project are to create awareness about the problem of counterfeiting medicines and their dangers, to collect data through collaboration by patients and consumers, pharmacies, quality control laboratories and well as to report to a central point (possible WHO) and make information available for use. The project also aims to find new approaches on how to combat counterfeiting and provide training in this area. FIP has developed a Counterfeit Website under its general websites: [www.fip.org](http://www.fip.org); [www.pharmacistscombatcounterfeiting.org](http://www.pharmacistscombatcounterfeiting.org). This website is updated on a regular basis.
- The FIP Administrative Pharmacy Section is working together with the Essential Drugs and Medicines Policy Department of WHO in the preparation of an International Survey on drug policy and healthcare.
- FIP continues to be active in promoting the Global Network of Pharmacists Against Tobacco. The Network was established in order to facilitate collaboration between regional pharmaceutical forums, professional pharmaceutical associations and individual pharmacists in the area of smoking cessation and anti-tobacco activities. The website: [www.pharmacistsagainsttobacco.org](http://www.pharmacistsagainsttobacco.org) has been updated regularly.

## WHO Meetings Attended by FIP Representatives

- WHO NGO Advisory Group on Health Promotion, Geneva, Switzerland, 9<sup>th</sup> March 2007  
Represented by: Mrs Tana Wuliji

- International Health Workforce Conference, Geneva, Switzerland, 22<sup>nd</sup> to 23<sup>rd</sup> March 2007.  
Represented by: Mrs Tana Wuliji, Prof Claire Anderson, Prof Ian Bates
- WHO IMPACT meeting of the WG Communications, Geneva, Switzerland, 12<sup>th</sup> April 2007  
Represented by: Mr A.J.M. Hoek, Mr Xuanhao Chan
- WHO Partnership for Maternal, Newborn and Child health (PMNCH), first Partners' Forum, Dar es Salaam, Tanzania, 17<sup>th</sup> to 20<sup>th</sup> April 2007  
Represented by: Mr Heri Mchungu
- WHO / FIP Training Workshop on Pharmaceutical Development, with a Focus on Paediatric Formulations, Cape Town, South Africa, 16<sup>th</sup> to 21<sup>st</sup> April 2007  
Represented by: Dr Tom Sam
- WHO NGO Advisory Group on Health Promotion, Geneva, Switzerland, 30<sup>th</sup> April 2007  
Represented by: Mr Xuanhao Chan
- WHO Intergovernmental meeting on Pandemic Preparedness, Geneva, Switzerland, 19<sup>th</sup> to 23<sup>rd</sup> November 2007  
Represented by: Mr A.J.M Hoek, Mr Xuanhao Chan
- WHO 1<sup>st</sup> NGO consultation on health promotion, Geneva, Switzerland, 3<sup>rd</sup> December 2007  
Represented by: Mr Xuanhao Chan
- WHO 9<sup>th</sup> Technical consultation on Taskshifting, Geneva, Switzerland, 4<sup>th</sup> to 7<sup>th</sup> December 2007  
Represented by: Mr Xuanhao Chan
- WHO IMPACT General Meeting, Lisbon, Portugal 10<sup>th</sup> to 14<sup>th</sup> December 2007  
Represented by: Mr A.J.M Hoek, Mr Xuanhao Chan
- 122<sup>nd</sup> WHO Executive Board Meeting, Geneva, Switzerland, 21<sup>st</sup> to 24<sup>th</sup> January 2008  
Represented by: Dr K Midal, Mr A.J.M Hoek, Mr Xuanhao Chan, Ms Tana Wuliji
- 1<sup>st</sup> Global Health Workforce Alliance Global forum for Human Resources for Health, 6<sup>th</sup> March 2008, Kampala, Uganda  
Represented by: Dr K Midal, Mr A.J.M Hoek, Ms Tana Wuliji

## Documents Reviewed & Information Requests Answered

- WHO Interagency Emergency Health Kit 2007
- Patient Safety Solutions Field Review 2007
- WHO/FIP - Developing pharmacy practice: A focus on patient care. Handbook 2006 Edition.
- First draft of the WHO Model List of Essential Medicines for Children

- WHO Draft Working Document QAS/06.179/Rev.1 (Stability testing of APIs and pharmaceutical products)
- WHO draft Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property, A/PHI/IGWG/2/2
- WHO Collaborating Centre for Chemical Reference Substances. Report on the work in 2006 (reference PSM/QSM/2007.6)
- QAS/07.202: Procedure for assessing the acceptability, in principle, of active pharmaceutical ingredients for use in pharmaceutical products
- QAS/07.237: Procedure for assessing the acceptability, in principle, of TCu380A IUDs for purchase by United Nations and other agencies
- QAS/07.238: Procedure for assessing the acceptability, in principle, of male latex condoms for purchase by United Nations and other agencies
- QAS/07.239: Proposal for revision: good manufacturing practices (GMP) for active pharmaceutical ingredients (APIs)
- QAS/07.240: WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce. Proposal for improvement
- WHO Working document QAS/07.242 Draft General international pharmacopoeia monograph for radiopharmaceuticals
- WHO Working document QAS/07.243 Draft monographs for individual radiopharmaceutical preparations
- QAS/07.247: Guideline on active pharmaceutical ingredient master file (APIMF) procedure
- QAS/07.248: Procedure for prequalification of medicinal products
- QAS/07.249: Cycloserine. Draft proposal for The International Pharmacopoeia
- QAS/07.250: Cycloserine capsules. Draft proposal for The International Pharmacopoeia
- QAS/08.251: Draft pharmaceutical development for multisource (generic) pharmaceutical products
- QAS/08.252: Proposal for revision of WHO Good Distribution Practices for pharmaceutical products
- QAS/08.256: Guideline to the inspection of hormone product manufacturing facilities
- QAS/08.257: Points to consider in the development of paediatric medicines: pharmaceutical development

## WHO Representatives at FIP Meetings

- Several Representatives from WHO attended the 67<sup>th</sup> World Congress of Pharmacy and Pharmaceutical Sciences in Beijing, China, as participants and/or speakers.



# Progress Report: Global Pharmacy Education Taskforce

The Global Pharmacy Education Taskforce is convened by FIP as a collection of stakeholders representing various global, regional and national networks with the goal of coordinating and catalyzing action to develop pharmacy education. The following summarizes and highlights the recent developments and profound steps that have been taken within this multi-faceted Taskforce to accomplish the aforementioned objective.

It was in September 2007 that the second Global Pharmacy Education Consultation was held at the FIP congress in Beijing with WHO and UNESCO. The focus of the consultation was to build consensus on an Action Plan that would seek to facilitate comprehensive pharmacy education and development to be carried out by the Pharmacy Education Taskforce. With an emphasis on concrete action, attainable goals and tangible results, the Action Plan identified three key areas of focus - quality assurance, academic workforce and institutional capacity, vision for pharmacy education and competency.

## Working with WHO, UNESCO and other international partners

Formal discussions for collaboration with WHO and UNESCO were initiated in November of 2007 where an agreement was reached to work together in the Pharmacy Education Taskforce. This unique tripartite partnership worked to produce the finalization of the 2008-2010 Action Plan in January 2008 with endorsement by the FIP Bureau. The work on the Action Plan came to fruition on March 6<sup>th</sup> 2008 when it was officially launched with WHO and UNESCO at the Global Health Workforce Alliance Global Forum in Kampala, Uganda.

In February 2008 FIP was officiated as a partner of the Avicenna directories and participated in the first meeting of the advisory group ([www.avicennadirectories.org](http://www.avicennadirectories.org)). The Avicenna directories will be the first online comprehensive directory of medical, public health and pharmacy schools (thus replacing the current world list of pharmacy schools). Other partners include WHO, World Federation for Medical Education, UNESCO, World Federation of Public Health Associations, Foundation for Advancement of International Medical Education and Research, International Association of Medical Regulatory Authorities and will be hosted at the University of Copenhagen.

## New Taskforce Structure

A Terms of Reference to operationalise the Taskforce with a new structure fit to implement the Action Plan was developed and adopted by the FIP Executive Committee in March 2008. The Terms of Reference will establish a regionally representative Taskforce Advisory Group, Project Leads, Project Teams, network of pharmacy schools and partners to support the implementation of the Action Plan. The FIP Bureau and Executive Committee will continue to oversee the progress of the Taskforce and Prof Henri R. Manasse will serve as the Bureau Committee Liaison to the initiative. A Program Director and Communications Liaison are being appointed to provide operational support and coordinate internal and external communication. Current Taskforce members who have initiated development thus far will continue to contribute in the advisory group and project teams.

## Pharmacy Education Action Plan Progress

The Pharmacy Education Action Plan 2008-2010 was developed through two global consultations before coming to a consensus on the following objectives on three priority domains of quality assurance, academic and institutional capacity, vision for pharmacy education and competency:

1. To define pharmacy service competencies across all settings and levels of the health system.
2. To set educational objectives aligned with competencies and develop a framework that considers the entire pharmacy education continuum from undergraduate education through to continuing professional development at the post-graduate level.
3. To develop a global framework for quality assurance and the development of accreditation systems (e.g. development of standards for educational institutions and programs) in pharmacy education.
4. To gather and analyse data on academic/faculty workforce, and review and develop capacity development strategies that meet local, regional or global needs.
5. To guide stakeholders towards an accepted holistic vision for the entire continuum of pharmacy education at global, regional and local levels.
6. To provide advocacy and technical guidance to country level stakeholders and educational institutions.
7. To establish a global platform for ongoing dialogue, sharing of evidence, practices, lessons learnt, resources and tools for pharmacy education and workforce planning.

Project Team Leads to steer activities in each priority domain were appointed in March 2008. Mr Mike Rouse, convener of the International Forum for Quality Assurance in Pharmacy Education was appointed Project Lead for quality assurance. Professor Claire Anderson, past president FIP Academic Section will be the Project Lead for academic workforce and institutional capacity. Professor Ian Bates, Vice-President European Association of Faculties of Pharmacy will be the Project Lead on developing a vision for pharmacy education and competency framework. These Project Team Leads have developed Project Plans within each domain and are in the process of forming Project Teams comprised of active expert contributors.

A proposal was developed to establish a network of schools of pharmacy (representative of all regions) to participate in the Action Plan process, contribute towards consultations, share experiences and resources, provide data and assist with field testing of tools and frameworks. Such a network will be

open and participatory and it is intended that the network will broaden over the course of the Action Plan. Expressions of interest from over 20 universities who have participated in the global consultations and Taskforce activities thus far were received. An application from this network was submitted to UNESCO as part of the university network program UNITWIN in April 2008.

Other steps taken by the Pharmacy Education Taskforce to achieve the objectives of the Action Plan include the submission of articles describing the Action Plan process and concept of needs-based education to the American Journal for Pharmacy Education (AJPE) and Human Resources for Health (HRH) journals for publication in mid to late 2008. These articles having been submitted to prominent journals work to raise support and awareness of the purpose and aims of the Taskforce as well as provide an international mechanism by which communication with a global audience can be accomplished.

## Next steps

The Pharmacy Education Taskforce is always looking ahead, and there are developments in the works for upcoming conferences and meetings that will help to strengthen and expand the scope of the Taskforce. Among these is a session to be held by the Taskforce during the American Association of Colleges of Pharmacy (AACP) in Chicago in July of 2008 entitled 'First do no harm: collaboration vs colonization' to align with the conference themed 'global pharmacy.' The Taskforce will take part in a Plenary Panel and Discussion -Education and Workforce Issues, Developing & developed countries' education at the International Social Pharmacy Workshop in New Zealand in July 2008 in addition to running a focus group workshop on culture and competency to be held during the conference. This is aimed at better understanding what 'competency' means to different cultures and how to break barriers associated with the topic. Further global consultation will take place at the 2008 FIP congress in Basel at a parallel session on Wednesday September 3<sup>rd</sup>.

Thus significant progress has been made by the Pharmacy Education Taskforce. With the tripartite partnership between WHO, UNESCO and FIP, a network of universities in the making, project plans in place, it is clear that there is an exciting future ahead for this initiative and the impact is anticipated to be hugely beneficial on a global scale. There is much anticipated of this group, and the Taskforce together with the FIP Bureau and partners WHO and UNESCO are doing the utmost to ensure the proper action is in motion to fulfill the goals of the Pharmacy Education Action Plan 2008-2010.





# Finance Report

## Statement of Income and Expenditure for the Year Ended December 31<sup>st</sup>, 2007

(Expressed in EUR)

		Actuals 2007	Budget 2007	Budget vs actuals	Actuals 2006
<b>INCOME</b>					
Membership fees	9	851 808	820 000	31 808	855 978
FIP World Congress revenues	10	1 543 017	1 366 000	177 017	1 197 701
PSWC Congress revenues	22b	1 442 428	1 130 455	311 973	-
Publications	11	2 202	5 000	( 2 798)	409
Other income BPP	19	-	-	-	3 524
Other income BPS	20	3 094	-	3 094	28 122
Sections income	23/24	180 914	120 000	60 914	308 442
Other income	12	19 604	5 000	14 604	19 459
<b>TOTAL INCOME</b>		<b>4 043 067</b>	<b>3 446 455</b>	<b>596 612</b>	<b>2 413</b>
<b>EXPENSES</b>					
Personnel costs	13	698 143	725 000	( 26 857)	645 342
Office costs	14	178 197	215 000	( 36 803)	193 656
Meeting costs	14	147 395	145 000	2 395	149 807
Travel expenses Ext. Representation	14	80 157	35 000	45 157	65 011
Website and IT-costs		44 995	55 000	( 10 005)	33 062
Depreciation of fixed assets	1	19 054	35 000	( 15 946)	21 398
Special Projects (incl. Regional Forums)	15	26 423	40 000	( 13 577)	6 156
Direct FIP World congress costs	16	971 811	792 500	179 311	697 421
PSWC Congress costs	22b	1 047 808	1 130 455	( 82 647)	-
Publications	17	61 569	60 000	1 569	54 879
Subventions	18	28 500	8 500	20 000	8 500
Expenses BPP	19	118 430	101 345	17 085	92 763
Expenses BPS	20	62 279	48 655	13 624	63 356
Sections costs	23/24	183 150	120 000	63 150	129 627
Maintenance Fund	7	10 000	10 000	-	-
Others		-	5 000	( 5 000)	-
<b>TOTAL EXPENSES</b>		<b>3 677 911</b>	<b>3 526 455</b>	<b>151 456</b>	<b>2 160 978</b>
<b>OPERATING RESULT</b>		<b>365 156</b>	<b>( 80 000)</b>	<b>445 156</b>	<b>252 657</b>
Financial result	21	( 59 592)	5 000	( 64 592)	( 36 423)
<b>NET RESULT BEFORE APPROPRIATION</b>		<b>305 564</b>	<b>( 75 000)</b>	<b>380 564</b>	<b>216 234</b>



# FIP Contact Details

## Fédération Internationale Pharmaceutique International Pharmaceutical Federation

Street Address:	Postal Address:
Andries Bickerweg 5	PO Box 84200
2517 JP The Hague	2508 AE The Hague
The Netherlands	The Netherlands

Website: [www.fip.org](http://www.fip.org)

### Secretariat and General Inquiries

Tel: +31-70-302-1970  
Fax: +31-70-302-1999  
Email: [secretariat@fip.org](mailto:secretariat@fip.org)

### Congresses and Conferences:

Tel: +31-70-302-1982  
Fax: +31-70-302-1998  
Email: [congress@fip.org](mailto:congress@fip.org)

### Marketing and Public Relations

Tel: +31-70-302-1978  
Fax: +31-70-302-1999  
Email: [marketing@fip.org](mailto:marketing@fip.org)

### Professional and Scientific Affairs:


Tel: +31-70-302-1988  
Fax: +31-70-302-1999  
Email: [profession@fip.org](mailto:profession@fip.org)


### Publications and Press

Tel: +31-70-302-1987  
Fax: +31-70-302-1999  
Email: [press@fip.org](mailto:press@fip.org)

### Membership

Tel: +31-70-302-1970  
Fax: +31-70-302-1999  
Email: [membership@fip.org](mailto:membership@fip.org)





**FIP**  
**Fédération Internationale Pharmaceutique**  
**International Pharmaceutical Federation**

*Street Address:*  
Andries Bickerweg 5  
2517 JP The Hague  
The Netherlands

P.O. Box 84200  
2508 AE The Hague  
The Netherlands

Tel.: +31-70-3021970 · Fax: +31-70-3021999  
E-mail: [fip@fip.org](mailto:fip@fip.org) · Website: [www.fip.org](http://www.fip.org)